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I. INTRODUCTION 
The Dust Bowl seemed to sweep down upon an unsuspecting 
people from out of nowhere.  Yet now, when we look back, we 
wonder how we could have been so foolish as to allow the reckless 
and ruthless plowing of so much of the Plains.1 
Today, U.S. livestock production relies heavily on antimicrobials, 
hormones, and a variety of other pharmaceuticals.  A number of 
concerns have been raised about these developments, including the 
presence of drug residues in meat and the impact of these production 
techniques on animal welfare.  This article, however, focuses 
particularly on an issue that has not received attention—the potential 
environmental impact associated with this pervasive use of 
pharmaceuticals.  It questions whether our use of drugs in livestock 
production, in combination with the concentration of production, can 
be likened to farmers’ naïve plowing of the Plains in the 1930’s.  Like 
 
 1.   See generally TIMOTHY EGAN, THE WORST HARD TIME: THE UNTOLD STORY OF 
THOSE WHO SURVIVED THE GREAT AMERICAN DUST BOWL (Anton Mueller ed., 2006) 
(relating the problems of people who lived through the Great Depression’s dust bowl). 
Appreciation is extended to Associate Dean Don Judges for his thoughts and inspiration 
regarding the connections between the dust bowl disaster and issues of environmental 
consequence today.  
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those farmers, we have beneficially increased the volume of what we 
produce.  But is our dependence on animal drugs reckless and 
ruthless when viewed in terms of the long-term environmental 
consequences?  Are we on our way to creating a new and different 
ecological disaster?  Will we look back and wonder how we could 
have been so foolish? 
This article will set the stage by providing an overview of the 
U.S. livestock industry.  It will emphasize how the industry has 
changed in the last several decades, noting the intensification of 
individual production facilities and the concentration of the industry 
in certain regions.  These changes have already had significant 
environmental impacts and additional risks will present going 
forward. 
The article will proceed to examine the industry’s overall 
dependence on pharmaceuticals.  There may be a passionate young 
movement toward antibiotic-free, hormone-free, and organic 
production.  Nevertheless, the industry standard and the vast majority 
of the meat and poultry production in the United States still depends 
on the use of antibiotics, hormones, beta-agonists, and other drugs 
used to sustain production levels.2  These drugs, in particular the 
antibiotics, enable intense confinement of animals in mega-facilities 
that house thousands of hogs and tens of thousands of chickens.3  The 
two billion animals that are raised in the United States each year 
produce over 1 billion tons of manure—manure that contains residues 
of many of the drugs these animals were given.4 
Following this examination, the article will describe the 
regulatory process in place for the approval of animal drugs and 
argue that this process is insufficient and ineffective.  As will be 
shown, more robust regulation faces significant impediments, 
 
 2.  See Lauren Orrico, Squashing the Superbugs: A Proposed Multifaceted Approach to 
Combatting Antibiotic-Resistant Bacteria, 27 J.L. & HEALTH 259, 263–64 (2014) (discussing that 
“cramped conditions [on factory farms are] ripe for bacterial epidemics” and that as a result, 
factory farms depend on antibiotics to combat “the spread of disease among animals kept in 
close quarters”).  
 3.  See id. (noting how animal feed containing antibiotics, hormones, and other materials 
is used to maintain high concentrations of animals in small areas and in unsanitary conditions).]  
 4.  See OCTAVIA CONERLY & LESLEY VAZQUEZ CORIANO, U.S.  ENVTL. PROT. 
AGENCY, EPA 820-R-13-002  LITERATURE REVIEW OF CONTAMINANTS IN LIVESTOCK AND 
POULTRY MANURE AND IMPLICATIONS FOR WATER QUALITY 5 (2013), available at 
http://water.epa.gov/scitech/cec/upload/Literature-Review-of-Contaminants-in-Livestock-and-
Poultry-Manure-and-Implications-for-Water-Quality.pdf (noting that the contaminants 
associated with manure can enter the environment through storage, handling, and land 
application). 
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including Congressional support for drug use in the livestock industry.  
This article concludes, that environmental advocates can confront 
these headwinds with strategies for change—by reordering industry 
priorities, increasing transparency, and reevaluating our means of 
production. These strategies can help us to prevent another ecological 
disaster. 
II. OVERVIEW OF U.S. LIVESTOCK PRODUCTION 
According to a recent U.S. Department of Agriculture (USDA} 
Economic Research Service report, the livestock industry in the 
United States has “undergone a series of striking transformations” in 
recent decades.5  Fifty years ago, the majority of livestock were 
produced on diversified independent farms—farms that were diverse 
in both the types of livestock and the variety of crops raised.6  Today, 
the majority of the livestock raised in the United States are produced 
on large specialized farms.7 
Specialization in this context may mean not only that farms are 
limited to a single species of animal, but that they raise that species 
only during a single stage of its life.  Large livestock operations 
“increasingly specialize in a single stage of livestock production, such 
as hog finishing,”8 with animals shifting from one specialized unit to 
another throughout their life cycle.9  Specialization is further evident 
in the careful breeding of one genetic line that meets processor 
expectations.10 
There has also been a dramatic increase in the size of livestock 
operations.  We have more than doubled the number of livestock and 
poultry produced, a figure that now exceeds over 2 billion head of 
livestock per year.  This development has coincided with an 80% 
decrease in the number of farms.  Most livestock and poultry are no 
 
 5.  JAMES M. MACDONALD & WILLIAM D. MCBRIDE, U.S. DEP’T. AGRIC., ECON. 
RESEARCH SERV., EIB- 43, THE TRANSFORMATION OF U.S. LIVESTOCK AGRICULTURE: 
SCALE, EFFICIENCY, AND RISKS iii (2009), available at http://www.ers.usda.gov/ 
media/184977/eib43.pdf [hereinafter TRANSFORMATION].  
 6.  JAMES M. MACDONALD ET AL., U.S. DEP’T. AGRIC., ECON. RESEARCH SERV., ERR-
152, FARM SIZE AND THE ORGANIZATION OF U.S. CROP FARMING 31 (2013), available at 
http://www.ers.usda.gov/media/1156726/err152.pdf. 
 7.   Id.   
 8.   TRANSFORMATION, supra note 5, at 1. 
 9.  See id. at 8 (explaining that most market hogs come from “feeder-to-finish” operations 
that involves pigs cycling through all three stages of hog production).   
 10.  See id. at 20 (noting that “controlling the genetics of their pigs and chicks” is one of the 
ways that processors assure uniformity to maintain processing efficiencies). 
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longer raised on pasture, but in confinement, allowing for greater 
control over the animals and larger numbers of animals per facility.11 
The EPA’s definition of a “Concentrated Animal Feeding 
Operation” (CAFO) for purposes of environmental regulation 
represents an attempt to accurately characterize these changes in the 
livestock industry.  An “Animal Feeding Operation” (AFO) is 
defined to be one where animals are confined and fed for 45 days or 
more in any 12-month period without grazing or foraging access.12  A 
CAFO is an AFO that has been designated as a point source for 
water pollution under the Clean Water Act largely because of its size, 
as measured by the number of animals in the facility.13  The concept, 
as well as the regulatory definition of a CAFO, embodies the 
dominant approach to livestock production today.  A CAFO is “a 
production process that concentrates large numbers of animals in 
relatively small and confined spaces, and that substitutes structures 
and equipment (for feeding, temperature controls, and manure 
management) for land and labor.”14 
This “production process”—the transformed system of livestock 
production in the United States—is not based solely on economies of 
scale.  One of the technologies integral to this transformation is the 
use of drugs to enhance growth,15 alter the animals’ physiology,16 and 
provide short-term disease prevention while animals are under 
stress.17  This article will now look at current production practices 
within four of the major livestock industries—the swine industry, the 
poultry industry (focusing on broiler production), the dairy industry, 
and the beef cattle industry—to set the stage for examining drug use 
within these industries and the resulting environmental concerns. 
A.  The Swine Industry 
As a USDA report from 2008 noted, “[t]oday’s hog sector bears 
little resemblance to the one that existed 15 years ago . . . .  There are 
 
 11.   See id. at 1 (describing how livestock are fed in confined areas with automated feed 
milling and delivery, grouped according to certain characteristics for feed formulas).  
 12.  40 C.F.R. § 122.23(b)(1)(i) (2014).  
 13.  40 C.F.R. § 122.23(b)(2).  
 14.  TRANSFORMATION, supra note 5, at 3.  
 15.  Id. at 32.  
 16.  Alberto Alemanno & Giuseppe Capodieci, Testing the Limits of Global Food 
Governance: The Case of Ractopamine, 3 EUR. J. OF RISK REG. 2 (2012) (describing 
Ractopamine as causing an “increase muscle leanness by inducing a redistribution of fat to 
muscle tissue in certain food animal species such as pigs and cattle”).   
 17.  TRANSFORMATION, supra note 5, at 32.   
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fewer hog farms, and the average number of hogs per farm has 
increased substantially.”18  In 1992, there were more than 240,000 
farms that raised hogs.  By 2004, less than 70,000 hog farms 
remained—a drop of over 70 percent.  Yet, the overall size of the U.S. 
hog inventory “remained stable at about 60 million head.”19 
Data from the 2012 Agricultural Census confirms the continued 
concentration of hog production on large farms.  Hog and pig sales in 
2012 totaled $4.4 billion, up 24.6 percent from the last census in 
2007.20  However, “[e]ven as the value of sales went up, the number of 
farms with hog and pig sales declined by 25 percent.”21  Farms that 
specialized in hog production declined by 29%.22  The bottom line is 
that more hogs are raised on fewer, larger specialized farms. 
Large hog facilities present complex manure management 
problems.  Data from the 2007 census were used to estimate that the 
hog industry alone generates over 111 million tons of manure per 
year.23 
Swine are typically housed over slatted floors, allowing manure 
to be washed down and routinely flushed out of the housing facility. 
Swine manure may be flushed to an underground pit (57% of 
operations), or another storage area like a manure pile (20% of 
operations).24 
In addition to concentration into larger facilities, these hog farms 
are now concentrated regionally.  Regional concentration exacerbates 
manure management problems as states contend with clusters of large 
confinement facilities.  Iowa, the top hog producing state, was 
responsible for 27 percent of swine production in 2007.25  Iowa hogs 
 
 18.   NIGEL KEY & WILLIAM D. MCBRIDE, U.S. DEP’T AGRIC., ECON. RESEARCH SERV., 
TECHNOLOGY, LARGER FARM SIZE INCREASED PRODUCTIVITY ON U.S. HOG FARMS 17, 
AMBER WAVES (Apr. 2008), available at http://www.ers.usda.gov/amber-waves/2008-
april/technology,-larger-farm-size-increased-productivity-on-us-hog-
farms.aspx#.VRLcu8ZX80k. 
 19.   Id. at 18.  
 20.   U.S. DEP’T. AGRIC., NAT’L AGRIC. STATISTICS SERV., ACH12–4, 2012 CENSUS 
HIGHLIGHTS, HOG AND PIG FARMING 1 (2014), available at http://www.agcensus.usda.gov/ 
Publications/2012/Online_Resources/Highlights/Hog_and_Pig_Farming/#industry [hereinafter 
HOG AND PIG FARMING]. 
 21.   Id. 
 22.   Id. 
 23.   CONERLY & CORIANO, supra note 4, at 7, tbl.2-2. 
 24.    Id. at 9 (citing Richard.W. Gullick et al., AWWA RESEARCH FOUND. & UNITED 
STATESENVTL. PROT. AGENCY., SOURCE WATER PROTECTION FOR CONCENTRATED 
FEEDING OPERATIONS: A GUIDE FOR DRINKING WATER UTILITIES (2007), available at 
http://waterrf.org/PublicReport Library/91159.pdf). 
 25.  Id. at 7, tbl.2-2. 
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and pigs produced over 31 million tons of manure that year.26  North 
Carolina, the second-largest hog-producing state in the country, 
raised 15.5% of U.S. swine, resulting in over 17 million tons of hog 
manure.27  The third-ranked state, Minnesota, was responsible for just 
over 11% of national production and contended with more than 12.7 
million tons of hog manure in 2007 alone.28  Farms in these three 
states alone “accounted for 55 percent of the value of U.S. hog and 
pig sales and 56 percent of the 66 million hog and pig end-of-year 
inventory in 2012.” 29 Unfortunately, concentration of production 
leads to a concentration of waste outputs as well.  This highly-
localized inundation of manure poses acute environmental risks. 
B.  The Poultry Industry 
The poultry industry follows a similar pattern.  The 2012 Census 
of Agriculture reported that U.S. poultry and egg sales totaled $42.8 
billion in 2012.30  This was a 15% increase since 2007.31  Yet, the 
Census also showed that the number of farms with poultry and egg 
sales decreased by 8%.32  Large, specialized farms accounted for 98% 
($42.0 billion) of sales in 2012.33 
The poultry business can be divided into production categories, 
with chicken production dwarfing the production of other fowl such 
as turkey, ducks, quail, geese, and others.  The 2012 Census of 
Agriculture estimates the U.S. inventory of chickens at 
1,506,300,000.34  In contrast, the turkey inventory was estimated to be 
just over 100 million.35 
Chicken production can be further divided into subcategories 
based on use: broilers and other chickens raised for meat, laying hens 
(including both those raised to produce table eggs and those raised to 
produce pullets for broiler production); and pullets (young chickens 
 
 26.  Id.     
 27.  Id.   
 28.  Id.  
 29. HOG AND PIG FARMING, supra note 20, at 1.  
 30.  USDA, NAT’L AGRIC. STATISTICS SERV., ACH12–18,  2012 CENSUS HIGHLIGHTS, 
POULTRY AND EGG PRODUCTION 1 (2015), available at http://www.agcensus.usda.gov/ 
Publications/2012/Online_Resources/Highlights/Poultry/Poultry_and_Egg_Production.pdf 
[hereinafter POULTRY AND EGG PRODUCTION].  
 31.   Id. 
 32.   Id. at 2.  
 33.   Id.   
 34.   Id.  
 35.   Id.  
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raised to replace the layers).36  A facility is typically designed to 
accommodate only one of these categories.37 
 1.  Broiler Production 
Broiler production is vertically integrated, with poultry 
processors controlling all aspects of production.38  While diversified 
farms of the previous generation had “chicken coops”—i.e., small 
structures with access to a yard or run—in today’s commercial 
chicken production, housing for a broiler’s short life is typically in a 
20,000 square feet rectangular building that is approximately 40 feet 
wide and 500 feet long.39  A house this size is used to produce 
115,000–135,000 birds in a year through confined growing conditions 
and one-flock-after-another production.40  Farmers are encouraged to 
build these houses in pairs, doubling annual production.41  Now, few 
growers still produce fewer than 100,000 broilers per year.  In fact, the 
production locus has grown from 300,000 broilers in 1987 to 520,000 
in 2002, to 600,000 by 2006.”42 
Poultry manure accumulates inside the broiler house, mixed with 
whatever bedding is provided.43  Broiler chickens in the United States 
produced over 52.7 million tons of manure in 2007.44 
Broiler production is concentrated along the Atlantic coast from 
Delaware south to Georgia, and in the southern states of Alabama, 
Mississippi, and Arkansas.45  Three southeastern states lead the 
nation—Georgia, with 14.7% of U.S. broilers, Arkansas, with 12.6%, 
and Alabama, with 11.1%.46  As in the hog industry, this means a lot 
of manure concentrated in a handful of states.  In 2007, Georgia was 
responsible for 7.7 million tons of manure, Arkansas for over 6.6 
million tons, and Alabama for over 5.8 million tons.47 
 
 36.   Id.  
 37.  Id.   
 38.  TRANSFORMATION, supra note 5, at 6 fig.1.  
 39.  Id. at 18.  
 40.  Id.  
 41.  Id. (referencing measurements from the 2006 ARMS broiler survey).  
 42.  Id. at 7.  
 43.  CONERLY & CORIANO, supra note 4, at 10.   
 44.  Id. at 8.   
 45. Poultry & Eggs: Background, U.S. DEP’T. AGRIC., ECON. RESEARCH. SERV., 
http://www.ers.usda.gov/topics/animal-products/poultry-eggs/background.aspx (last updated 
May 28, 2012).   
 46.  CONERLY & CORIANO, supra note 4, at 8.  
 47.  Id. 
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 2.  Egg Production 
The USDA National Agricultural Statistics Service estimates 
that the U.S. egg industry produced over 95 billion eggs in 2013.48  The 
most recent monthly report estimates that 8.63 billion eggs were 
produced in the United States in December 2014 alone, an amount 
that is up 3% from last year.49 
The egg industry has become very concentrated and operates 
under a corporate model.  According to the American Egg Board,50 in 
1994, approximately 350 companies had layer flocks of 75,000 hens or 
more.51  Today, that number has declined to 175 companies with 
flocks of 75,000 hens or more.52  However, these 175 companies 
“represent about 99 percent of all the hens in the United States.”53  Of 
these, there are “approximately 66 egg producing companies with 1 
million-plus hens.”54  These companies alone control approximately 
87 percent of total production.  Seventeen companies each have 
greater than 5 million hens.55 
It is estimated that there were 306 million layers in the United 
States at the end of 2014.56  Most layers are housed in elevated cages, 
allowing manure to accumulate below or drop onto a conveyor belt 
that removes manure from the building.57  Manure is typically washed 
from the housing facility to a storage pit.58  Estimates of total manure 
 
 48.  USDA NAT’L AGRIC. STATISTICS SERV., CHICKENS AND EGGS 2013 SUMMARY 7 
(2014), available at http://usda.mannlib.cornell.edu/usda/nass/ChickEgg//2010s/ 2014/ChickEgg-
02-27-2014.pdf.  
 49.  USDA NAT’L AGRIC. STATISTICS SERV., CHICKENS AND EGGS DECEMBER REPORT 4 
(2015), available at http://usda.mannlib.cornell.edu/usda/nass/ChicEggs//2010s/2015/ChicEggs-
01-23-2015.pdf.  
 50.    The American Egg Board is an organization funded through the congressionally 
created “checkoff” program that assesses a charge from companies with more than 75,000 layer 
chickens in the United States.  Egg Research and Consumer Information Act, 7 U.S.C. §§ 2701–
2718 (2012).  The AEB is run by a board that is appointed by the Secretary of Agriculture. 
About AEB, AM. EGG BD., http://www.aeb.org/about-aeb/about (last visited Mar. 1, 2015).  
 51.  Industry Overview, AMERICAN EGG BD., http://www.aeb.org/farmers-and-
marketers/industry-overview (last visited Mar. 1, 2015) [hereinafter Industry Overview].  
 52.  Id.   
 53.  Id.    
 54.  Id.    
 55.  Id.  
 56.  Id.  
 57.  CONERLY & CORIANO, supra note 4, at 10 (citing RICHARD.W. GULLICK ET AL., 
AWWA RESEARCH FOUND. & UNITED STATES. ENVTL. PROT. AGENCY., SOURCE WATER 
PROTECTION FOR CONCENTRATED FEEDING OPERATIONS: A GUIDE FOR DRINKING WATER 
UTILITIES 1 (2007), available at http://waterrf.org/PublicReport Library/91159.pdf).  
 58.  Id. (referencing Zhao et al., Hormones in Waste from Concentrated Animal Feeding 
Operations, in FATE AND TRANSPORT OF PHARMACEUTICALS IN THE ENVIRONMENT AND 
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production associated with egg production are difficult to find.  
However, the USDA estimates that layer chickens produce 
approximately 60.5 lbs. of manure per day per 1000 lbs. of animal 
unit.59  Like each of the previously discussed industries, egg 
production is regionally concentrated.  Five states—Iowa, Ohio, 
Indiana, Pennsylvania, and Texas—represent approximately 51% of 
all U.S. egg production,60 and thus find themselves responsible for a 
majority of the nation’s chicken waste. 
C.  The Cattle and Dairy Industries 
The beef cattle and dairy industries are obviously related; both 
depend on cattle and both contribute to the supply of beef available 
to consumers.  They are, however, profoundly different in structure 
and production methods. 
 1. The Dairy Industry 
The dairy industry has also exhibited a dramatic transformation 
with fewer farms and a production shift to farms that are significantly 
larger in size.  The 2012 Census of Agriculture estimates that there 
were 9.3 million milk cows in the United States at the end of 2012.61  
This was down 0.2% from 2007, although the number of farms 
involved declined by 8% during that time period.62 
This trend has been ongoing for some time.  Between 1997 and 
2007, dairy production remained relatively stable, while the number 
of dairy farms in the United States dropped by nearly 50%.63  Recent 
USDA estimates indicate that the number of dairy farms fell by 
nearly 60% over the past 20 years, even as total milk production 
increased by one-third.64  The production locus or midpoint (the 
measurement of the size of a farm at which half of production would 
 
WATER TREATMENT SYSTEMS (Diana S. Aga, ed., 2008)).  
 59. Animal Manure Management, U.S. DEP’T AGRIC., NATURAL RES. CONSERVATION 
SERV.  (1995), http://www.nrcs.usda.gov/wps/portal/nrcs/detail//?cid=nrcs143_014211#table1.  
 60.  Industry Overview, supra note 51. 
 61.  USDA NAT’L. AGRIC. STATISTICS SERV., ACH12–14, 2012 CENSUS HIGHLIGHTS, 
DAIRY CATTLE AND MILK PRODUCTION 1 (2014), available at http://www.agcensus.usda.gov/ 
Publications/2012/Online_Resources/Highlights/Dairy_Cattle_Milk_Prod/Dairy_Cattle_and_Mi
lk_Production_Highlights.pdf.  
 62.  Id.  
 63. CONERLY & CORIANO, supra note 4, at 11.  
 64.  James MacDonald & Doris Newton, Milk Production Continues Shifting to Large-
Scale Farms, U.S. DEP’T AGRIC., ECON. RESEARCH SERV. (Dec. 1, 2014), 
http://www.ers.usda.gov/amber-waves/2014-december/milk-production-continues-shifting-to-
large-scale-farms.aspx#.VM7MOFXF-l1.  
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come from larger farms and half from smaller) shifted dramatically 
from 80 cows in 1987 to 275 by 2002.65  By 2012 it was 900 cows, and 
“farms with at least 1,000 cows accounted for 49 percent of all cows.”66 
The large size and active metabolism of a lactating cow result in a 
tremendous volume of associated waste.  It is estimated that, on 
average, a lactating dairy cow will generate 50 liters of manure, 
including urine, every single day.67  The University of Wisconsin 
Agricultural Extension Service developed a chart for farmers to 
compute manure production from their herd.  For one average 1400 
lb. dairy cow, the chart estimates that 21.9 tons of manure per year 
will be produced.68 
Dairy production is concentrated in California and Wisconsin; 
together these states account for a third of U.S. dairy sales.69  The top 
ten states account for nearly three-fourths of sales.70  Following 
California and Wisconsin, these states, in order of production, are 
New York, Idaho, Pennsylvania, Texas, Minnesota, Michigan, New 
Mexico, and Washington.71 
 2.  The Beef Cattle Industry 
The United States boasts “the world’s largest fed-cattle 
industry,” and is also the “world’s largest producer of beef.”72  It is 
known for its grain-fed beef for domestic and export markets. 
Feedlots provide for “finishing” and preparing cattle for 
slaughter.  There, they are fed a high-energy ration that is 70–90% 
grain and protein concentrate.73  They are usually in the feedlot for 
about 140 days, with variations between 90 and 300 days reported.74  
Their average weight gain is 2.5–4 pounds per day based on 6 pounds 
of feed per pound of gain.75 
 
 65.   TRANSFORMATION, supra note 5, at 5–6.  
 66.   MacDonald & Newton, supra note 64.  
 67.  CONERLY & CORIANO, supra note 4, at 5.  
 68.  UNIV. OF WIS. EXTENSION SERV., HOW MUCH FERTILIZER DO YOUR ANIMALS 
PRODUCE? 1, available at http://learningstore.uwex.edu/assets/pdfs/a3601.pdf (last visited March 
2, 2015).  
 69.  U.S. DEP’T AGRIC., NAT’L. AGRIC. STATISTICS SERV., supra note 61, at 1.  
 70.  Id.  
 71.  Id.  
 72.  Cattle and Beef, Cattle Background, USDA ECON. RESEARCH SERV. (May 26, 2012),  
http://www.ers.usda.gov/topics/animal-products/cattle-beef/background.aspx [hereinafter Cattle 
and Beef].  
 73.  Id.   
 74.  Id.  
 75.  Id.  
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Today, feedlots represent the concentrated and the 
“industrialized stage” of the cattle sector.76  Again, however, this is a 
change from prior production practices.  Individual farms and small 
local feedlots were the norm until at least the mid-1960s.  “In 1964, 
feedlots with capacities of less than 1,000 head handled over 60 
percent of U.S. fed-cattle marketings.”77 
Since that time, there has been a marked shift of the industry 
toward large commercial feedlots, particularly those located in the 
Great Plains and the West.  These feedlots house tens of thousands of 
cattle at a time, purchase feed ingredients, maintain their own 
feedmills, and “employ nutritionists, veterinarians, and sales and 
management staff.”78 
Feedlots with capacity for 1,000 head or more now market 
between 80 and 90% of fed cattle.79  Feedlots with capacity for 32,000 
head or more sell approximately 40% of the fed cattle market.80  “The 
largest feedlots can feed 100,000 cattle at a time.  Some are owned by 
meatpackers, some are part of larger diversified firms, and others are 
specialized cattle feeding businesses, sometimes with a feed 
production enterprise as well.”81 
D.  Summary: Livestock Production Today 
The U.S. livestock and poultry industry produces over 2 billion 
animals per year.82  Most of these animals are being raised in 
conditions and in concentrations that are relatively novel, as the 
industry has seen a rapid and dramatic transformation.83  Within just 
the last fifty years, we have moved from production on diversified and 
dispersed smaller farms to large-scale industrial-style production that 
both concentrates animals in confined facilities, and that are 
concentrated themselves in specific regions of the country.84  This can 
be said with regard to each major category of livestock that we 
produce.85 
 
 76.  TRANSFORMATION, supra note 5, at 12.  
 77.  Id.  
 78.  Id.  
 79.  Cattle and Beef, supra note 72.  
 80.  Id.  
 81.  TRANSFORMATION, supra note 5, at 12.  
 82.  CONERLY & CORIANO, supra note 4, at 1.  
 83.  Id.  
 84.  Id.  
 85.  Id.  
11-Schneider_Final (Do Not Delete) 8/17/2015  5:20 PM 
Spring 2015] BEYOND THE FOOD WE EAT 239 
Livestock and poultry produced in the United States generate 
over one billion tons of manure each year.86  In reasonable quantities, 
and applied to land appropriately, manure can improve soil quantity 
and provide essential nutrients for plant growth.87  However, when 
concentrated in large quantities, manure can also degrade surface 
water quality, pollute the air, and spread disease.88  Most concerns 
about concentrated livestock production and manure have focused on 
phosphorus and nitrate contamination associated with manure runoff 
and spills.  Some, however, have also raised the alarm that the drugs 
given to the livestock and present in the manure are another cause for 
serious concern.89 
It is not the purpose of this article to criticize the shift in 
agricultural production per se.90  Rather, this article argues that the 
current use of livestock drugs—drugs that in many instances make 
concentrated production feasible—raises serious environmental and 
public health risks.  The next section of this article will discuss how 
these drugs are used and their capacity to impact the environment. 
III. THE USE OF PHARMACEUTICALS IN LIVESTOCK PRODUCTION 
The transformation of the livestock industry has been largely 
driven by efforts to decrease production costs.  Producing more meat 
at a cheaper price has been the driving influence of a very competitive 
industry. 
New technologies both support and encourage this objective.  
Technological innovations initially offer opportunities for expanded 
production and reduced costs, but then become the norm, forcing all 
producers to adapt or else compete at a price disadvantage.91  
 
 86.  Id. at 5.  
 87.  Id.  
 88.  See id. at 1 (identifying environmental problems caused by manure concentration). 
 89.  Id.  
 90.  This author has expressed that view previously. See, e.g., Susan A. Schneider, 
Reconsidering the Industrialization of Agriculture, 26 J. ENVTL. L. & LITIG. 19 (2011) (arguing 
that external costs associated with large scale industrial production systems should be 
considered and challenging the efficiency of these systems when these costs are included).  
Many others have raised persuasive, passionate arguments about the broader consequences of 
industrial agriculture including its impact on rural communities, the environment, and the 
welfare of the animals raised.  See, e.g., Neil D. Hamilton, Essay – Food Democracy and the 
Future of American Values, 9 DRAKE J. AGRIC. L. 9 (2004) (discussing the changes in 
agriculture and the changes in the U.S. food system). 
 91.  This phenomenon is referred to as the “technology treadmill.”  See Susan A. 
Schneider, FOOD, FARMING, AND SUSTAINABILITY: READINGS IN AGRICULTURAL LAW 19 
(2011) (referencing the work of Willard Cochrane). 
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Mechanical innovations have allowed producers to reduce labor costs, 
while chemical innovations have created pesticides that have 
decreased pest loss and increased crop yields.92  Biological 
innovations—including breeding animals for specialized traits and 
using a variety of animal drugs—have had a dramatic impact on 
livestock production, reducing costs and increasing the volume and 
speed of production. 
 
New technologies often reduce costs directly, by allowing more 
meat and milk to be produced for a given amount of land, feed, 
labor, and capital.  But the new technologies also create economies 
of scale, which reduce costs more for larger operations.  As a 
result, larger farms realize higher profits, on average, which 
provides a strong incentive for operators to grow.  In turn, lower 
industry-wide farm costs lead to lower prices for farm commodities.  
Lower prices can squeeze smaller farms with higher costs, causing 
many to exit, grow, or explore niche markets for differentiated 
products.93 
 
Unfortunately, these new technologies often create new 
problems, and the most common response has been the development 
of an additional new technology to address the problem.  For 
example, the overuse of the pesticide Glyphosate (RoundUp) has 
resulted in the development of resistant “super weeds.”94  In response, 
farmers are increasing the quantities of Glyphosate used and are 
using more virulent pesticides, as well.95  The seed/chemical industries 
suggest new pesticide/genetic modification technologies, and so the 
treadmill continues.96 
In livestock agriculture, animal science researchers have focused 
on developing drugs to provide greater efficiencies and/or to address 
the problems caused by industrial production.  This has been a 
lucrative market for the pharmaceutical industry.97 
 
 92.  Id.  
 93.  TRANSFORMATION, supra note 5, at 2.  
 94.  Neil D. Hamilton, Don't Repeat Mistakes That Led To Superweeds, DES MOINES REG. 
(June 28, 2014), http://www.desmoinesregister.com/story/opinion/columnists/iowa-view/2014/ 
06/28/repeat-mistakes-led-superweeds/11652199/.  
 95.  Id.  
 96.  Id.  
 97.  “The 2007 U.S. Census of Manufacturing reports that total U.S. revenues from 
veterinary pharmaceuticals are over $5.41 billion.”  Brian L. Buhr et al., Health Competition in 
the Animal Health Industry, CHOICES, http://www.choicesmagazine.org/magazine/article.php? 
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This article will next discuss the most common categories of 
drugs used in livestock production and the extent of their use.  
Throughout this discussion, however, only estimates are provided, 
sometimes expressed within a relatively wide range.  This is because 
there is no publicly available accurate data for drug use in the 
livestock industry.  Moreover, such information is generally not even 
available to the government agency that regulates its use.  Most 
livestock drugs are sold “over-the-counter” without a prescription.  
On-farm reporting is not required; most drugs are available without 
veterinary supervision; and both feed recipes and drug use may be 
considered proprietary information by industry.98  Pharmaceutical 
companies are now required to provide the Food and Drug 
Administration (FDA) with some data on the total sales of certain 
antibiotics sold for use in food animals.  However, this data does not 
reveal the animal species related to the purchase; the geographic 
region of use; the purpose of the use (whether for disease prevention, 
treatment, or growth promotion); nor the actual use or dosage.99 
A.  Antimicrobials 
It is estimated that between 60 and 80% of all livestock and 
poultry produced in the United States routinely receive 
antimicrobials of one type or another, most often at “sub-
therapeutic” levels.100  The majority of this use is estimated to be for 
 
article=164 (last visited Mar. 31, 2015). 
 98.  See CONERLY & CORIANO, supra note 4, at 28 (discussing antimicrobials); Id. at 40 
(discussing hormones); see also U. S. GOV’T ACCOUNTABILITY OFFICE, GAO-04-490, 
ANTIBIOTIC RESISTANCE: FEDERAL AGENCIES NEED TO BETTER FOCUS EFFORTS TO 
ADDRESS RISKS TO HUMANS FROM ANTIBIOTIC USE IN ANIMALS (2004) (calling upon the 
USDA and the HHS to develop strategies for data collection on use in the livestock industry). 
 99.  The FDA recently proposed a rule that would take a first step to collect additional 
data.  The rule would require animal drug manufacturers to track the sale of antibiotics by 
particular species, allowing FDA to determine which are sold for use in chicken, cattle, pigs, 
turkeys, and other food-producing animal production.  The rule would not reveal specific on-
farm usage.  Antimicrobial Animal Drug Sales and Distribution Reporting, 80 Fed. Reg. 28,863 
(proposed May 20, 2015) (to be codified at 21 C.F.R. pt. 514); see also ANTIBIOTIC USE IN 
ANIMALS, GAO-04-490 at 92 (FDA response to GAO recommendation that more data on 
usage should be sought and maintained).  
 100.  This refers to a dosage that would generally be insufficient for medicinal therapy to 
treat an active infection but that provides other benefits to production, e.g., growth promotion 
and possible disease prevention. While this term has been used extensively, the FDA now 
prefers the term “production use” as it views the terms “nontherapeutic” and “subtherapeutic” 
as “terms that we believe lack sufficient clarity.” FOOD & DRUG ADMIN., GUIDANCE FOR 
INDUSTRY: THE JUDICIOUS USE OF MEDICALLY IMPORTANT ANTIMICROBIAL DRUGS IN 
FOOD-PRODUCING ANIMALS 4 n.3 (Apr. 13, 2012), available at http://www.fda.gov/ 
downloads/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/UCM21
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the purpose of enhancing growth and increasing feed conversion 
ratios rather than for medicinal reasons.101  In 2010, over 29 million 
pounds of antimicrobials were sold for livestock production use, an 
amount that is estimated to be “3–4 times the amount used by 
humans.”102  Ninety percent of these antimicrobials are estimated to 
be delivered through the animals’ feed or water, and so provided to 
all of the animals at once, en masse.103 
The routine use of antibiotics in livestock and poultry production 
has been increasingly controversial, as the connection between 
overuse in the livestock industry and the development of antibiotic 
resistance has been confirmed.104  Antibiotic resistance is considered 
to be one of the major public health concerns worldwide.  According 
to the World Health Organization, “[a]ntimicrobial resistance (AMR) 
threatens the effective prevention and treatment of an ever-
expanding range of infections caused by bacteria, parasites, viruses, 
and fungi.  It is an increasingly serious threat to global public health 
that requires action across all government sectors and society.”105  The 
connection between agricultural use of antibiotics and antibiotic 
resistance was first publically acknowledged in the landmark Report 
of the Joint Committee on the Use of Antibiotics in Animal Husbandry 
and Veterinary Medicine, more commonly known as the Swann 
Report, published in Great Britain in 1969.106  This Report concluded 
that “the administration of antibiotics to farm livestock, particularly 
at sub-therapeutic levels, poses certain hazards to human and animal 
health;” and that it has led to resistant bacteria that can be transfered 
from animals to man.107 
 
6936.pdf [hereinafter JUDICIOUS USE].  
 101.  CONERLY & CORIANO, supra note 4, at 27.  
 102.   Id.  
 103.   Meghan F. Davis & Lainie Rutkow, Regulatory Strategies to Combat Antimicrobial 
Resistance of Animal Origin: Recommendations For a Science-Based Approach, 25 TUL. ENVTL. 
L.J. 327, 331 (2012). 
 104.   See JUDICIOUS USE, supra note 100, at 4 (finding that antimicrobial resistance is a 
“public health problem of global significance”).  
 105.  Antibiotic Resistance, WORLD HEALTH ORG. (Apr. 2014), http://www.who.int/ 
mediacentre/factsheets/fs194/en/. 
 106.   M.M. SWANN, ET AL., REPORT OF THE JOINT COMMITTEE ON THE USE OF 
ANTIBIOTICS IN ANIMAL HUSBANDRY AND VETERINARY MEDICINE, HMSO, London (1969).  
This Joint Committee was appointed by the Health and Agriculture Ministers in Great Britain 
in July 1968, and it was chaired by Professor M. M. Swann.  The committee’s report was issued 
in November 1969.  Its findings are still cited today, and they formed the basis for the eventual 
withdrawal of the approval for livestock use of many antimicrobials throughout Europe.  
 107.   House of Lords, Session 1997-98, Science and Technology Committee Reports: 
Science and Technology--Seventh Report, Ch. 3 Prudent Use In Animals, available at 
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In the United States, there has been a series of research studies 
and commission reports that have warned about the connections 
between antibiotic use in livestock production and antibiotic 
resistance.108  While there are clearly other causes of resistance, the 
link between the extensive use of antimicrobials in the livestock 
industry and the development of antibiotic resistance with respect to 
the specific drugs used, cannot reasonably be disputed.109  For 
example, in 2014, the President’s Council of Advisors on Science and 
Technology confirmed the link in its report to President Obama.  
Since retail meat can be a source of microbes, those antibiotic-
resistant microbes can be transmitted to consumers.  Even more 
alarming is the fact that “antibiotic resistance can spread between 
microbes (through the transfer of DNA elements, such as plasmids, 
between species) and antibiotic-resistant microbes can spread from 
animals to people who come into contact or close proximity with 
them.”110 
Nevertheless, the extensive use of antibiotics continues today in 
the livestock industry.  Recent FDA data shows an increase rather 
than a decrease in usage.  In September of 2014, the FDA issued its 
2012 summary report on the volume of antimicrobials sold for use in 
livestock.  It revealed that from 2009 to 2012, “[t]he total quantity of 
antimicrobial active ingredients sold or distributed for use in food-
producing animals increased by 16%.”111  It is estimated that as many 
 
http://www.parliament.the-stationery-office.co.uk/pa/ld199798/ldselect/ldsctech/081vii/st07 
06.htm.  It is telling to note that some of the specific antibiotics singled out by the Swann Report 
as “unsuitable” for animal use in 1969 are still in use today in livestock production in the United 
States.  
 108.  See, e.g., JENNY LI & DAVID WALLINGA, INST. FOR AGRIC. AND TRADE POL’Y, NO 
TIME TO LOSE: 147 STUDIES SUPPORTING PUBLIC HEALTH ACTION TO REDUCE ANTIBIOTIC 
OVERUSE IN FOOD ANIMALS (2012), available at http://www.iatp.org/files/ 
2012_11_08_AntibioticsBiliography_DW_JL_long_hyperlinks.pdf (describing the public health 
risks associated with antibiotic use in livestock production and providing a bibliography of 
studies documenting this risk).  
 109.  See JUDICIOUS USE, supra note 100, at 5–17 (describing the link between the use of 
antimicrobials in livestock and the development of antibiotic resistance). For a cogent 
explanation for how antibiotic resistance can stem from the use of antibiotics in livestock 
production, see Davis & Rutkow, supra note 103, at 335–37. 
 110.  PRESIDENT’S COUNCIL OF ADVISORS ON SCIENCE AND TECHNOLOGY, REPORT TO 
THE PRESIDENT ON COMBATTING ANTIBIOTIC RESISTANCE, 50–51 (Sept. 2014), available at 
https://www.whitehouse.gov/sites/default/files/microsites/ostp/PCAST/pcast_amr_sept_2014_fin
al.pdf.  
 111.  FOOD & DRUG ADMIN., DEPT. OF HEALTH & HUMAN SERV., 2012 SUMMARY 
REPORT ON ANTIMICROBIALS SOLD OR DISTRIBUTED FOR USE IN FOOD-PRODUCING 
ANIMALS 5 (Sept. 2014), available at http://www.fda.gov/downloads/ForIndustry/UserFees/ 
AnimalDrugUserFeeActADUFA/ UCM416983.pdf.   
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as 55% of the types of antibiotic compounds used in the industry are 
also used to treat human infections.112 
The resulting environmental impact of this antibiotic use is 
significant.  There are many pathogens that are associated with 
livestock production; some are only adapted for a particular animal 
species host, and others, termed zoonotic pathogens, are adapted to 
produce infections in humans.113  Some of these pathogens can be 
extremely dangerous, even aside from antibiotic resistance.114  For all 
of these pathogens, though, antibiotic resistance complicates 
treatment and raises additional dangers.115 
These antibiotic resistant pathogens can be found on the 
livestock, in their surroundings, and on the meat that is marketed to 
consumers; thus, it can be spread to those in contact with the animals, 
their surroundings, or their meat.116  Both the pathogens and the 
antimicrobials are found in the manure that is excreted.117  According 
to EPA: 
 
Antimicrobials are often only partially metabolized in livestock and 
poultry and can be excreted virtually unchanged as the parent 
compound.  For example, up to 80% of tetracyclines may be 
excreted by swine and poultry as the parent compound.  
Additionally, up to 67% of the macrolide tylosin, which is 
approved for use in beef cattle, dairy cows, swine, and poultry may 
be excreted by livestock and poultry when the antimicrobial is 
administered orally.118 
 
After excretion, the antibiotics interact with the environment 
when the manure is applied to land, carried in runoff, or associated 
 
 112. CONERLY & CORIANO, supra note 4, at 27. 
 113.  Id. at 13.  
 114.  See, e.g., Shiga Toxin-Producing Escherichia coli, 76 Fed. Reg. 58,157 (Sept. 20, 2011) 
(announcing the USDA Food Safety and Inspection Service’s decision to declare certain Shiga 
toxin-producing E. coli (STEC) as adulterants in non-intact raw beef products because of the 
seriousness of the illnesses caused).  
 115.  Antibiotic / Antimicrobial Resistance, CTR. FOR DISEASE CONTROL (Sept. 16, 2013), 
http://www.cdc.gov/drugresistance/about.html. 
 116.  Id.; see also The Trouble with Antibiotics (PBS Television Broadcast Oct. 14, 2014), 
available at http://www.pbs.org/wgbh/pages/frontline/trouble-with-antibiotics/ (presenting 
evidence of antibiotic resistant bacteria on meat and the genetic linking of the pathogens to 
specific infections in humans).  
 117.  CONERLY & CORIANO, supra note 4, at 35.  
 118.  Id.  
11-Schneider_Final (Do Not Delete) 8/17/2015  5:20 PM 
Spring 2015] BEYOND THE FOOD WE EAT 245 
with a spill.119  The occurrence of antimicrobials in soil, surface water, 
and ground water has been well documented, with “antimicrobial 
compounds present in 67 percent of ground water and surface water 
samples collected near poultry operations and 31 percent of ground 
water and surface water sample collected near swine operations.”120 
 
Because food-producing animals excrete 75% of the antimicrobials 
they consume unchanged or as active metabolites of the drug, 
antimicrobials not only apply selective pressure on the intestinal 
microbial community of the food-producing animal, but also on the 
microbiome of the animal's environment, such as the barn, pasture, 
and fields where manure is applied.  Spillage of medicated feed 
may contaminate local soils and waters.  The presence of 
antimicrobial drugs from these sources can influence the local 
microbial ecology, allowing resistant organisms to survive and to 
become more common in bacterial communities in and around 
concentrated animal feeding operations (CAFOs). Further, the 
CAFO environment, marked by crowding of animals in small, 
often indoor spaces, intensifies the spread of bacteria among 
animals and increases pathogen contamination of their barns or 
pens . . . .  Residents of rural communities may be exposed to 
antimicrobial pollution through air and water contaminated by 
manure waste, and consumers nationwide (and globally) can be 
exposed through the retail meat, seafood, or other products they 
contact, such as fertilizer derived from contaminated animal 
products.121 
 
A very recently published study confirms the transmission of 
antibiotics, bacteria, and antibiotic-resistant genetic materials by 
wind.  The study tested areas surrounding commercial feedlots.  The 
study found these substances not only at sites a distance from the 
feedlot, but also at greater levels downwind than upwind from the 
feedlot, confirming wind transmission.122 
 
 119.  Id.  
 120.  Id. at 36 (citing E.R. Campgnolo et al., Antimicrobial Residues in Animal Waste and 
Water Resources Proximal to Large-Scale Swine and Poultry Feeding Operations, THE SCIENCE 
OF THE TOTAL ENVIRONMENT 299: 89-95 (2002)).  
 121.   Davis & Rutkow, supra note 103, at 339–40.  
 122.  ANDREW D. MCEACHRAN ET AL., ENVTL. HEALTH PERSPECTIVES, ANTIBIOTICS, 
BACTERIA, AND ANTIBIOTIC RESISTANCE GENES: AERIAL TRANSPORT FROM CATTLE FEED 
YARDS VIA PARTICULATE MATTER (Jan. 22, 2015), available at http://ehp.niehs.nih.gov/wp-
content/uploads/advpub/2015/1/ehp.1408555.acco.pdf.   
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Public health professionals around the world have been 
expressing grave concerns about antibiotic resistance for some time.  
Yet, in the United States, we are only beginning to appreciate the 
significance of the environmental and public health threats posed by 
using so many antibiotics in our livestock industry.  It is time we 
acknowledge the risks we have created. 
B.  Hormones 
Hormones are produced naturally by animals, and the levels and 
kinds of hormones produced will be impacted by a variety of factors 
including growth, reproduction, other natural biological rhythms, and 
stress.  Some of the most ubiquitous hormones, produced throughout 
life, include estrogen, progesterone, and testosterone.  These natural 
hormones are “necessary for normal development, growth, and 
reproduction.”123 
A variety of steroid hormone drugs that supplement natural 
production have been approved for use in beef cattle and sheep since 
the 1950s.124  These approved drugs include estrogen, progesterone, 
and testosterone in natural and synthetic versions.125  These drugs are 
given to animals to increase their growth rate, to increase feed 
conversion ratios (the rate by which the animal converts feed to 
weight gain for meat production), to improve meat quality, and to 
affect reproduction.126 
According to the FDA, these drugs are typically administered in 
cattle and sheep as “pellets that are placed under the skin on the back 
side of the animal’s ear.  The pellets dissolve slowly under the skin.”127 
Typical cattle implants contain trenbolone acetate and estradiol 
benzoate.128  The FDA has not approved the use of exogenous steroid 
hormones in swine, poultry, veal calves, or dairy cows.129 
In addition to the pellet delivery system, beef cattle on feedlots 
may also receive daily doses of synthetic hormones (melengestrol 
 
 123.   FOOD & DRUG ADMIN., Steroid Hormone Implants Used for Growth in Food-
Producing (Oct. 14, 2014), http://www.fda.gov/AnimalVeterinary/SafetyHealth/ProductSafety 
Information/ucm055436.htm [hereinafter Steroid Hormone Implants].    
 124.  21 C.F.R. §§ 522, 556, 558 (2014); Steroid Hormone Implants, supra note 123; 
CONERLY & CORIANO, supra note 4 at 40–41.  
 125.  Id.  
 126.  Id.  
 127.  Steroid Hormone Implants, supra note 123.  
 128.  CONERLY & CORIANO, supra note 4, at 40.  
 129.  See Steroid Hormone Implants, supra note 123 (“No steroid hormones are approved 
for growth purposes in dairy cattle, veal calves, pigs, or poultry.”).  
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acetate) in their feed.130  Dairy cows often receive “intravaginal 
controlled internal drug release (CIDR) inserts” of progesterone “to 
control estrous (menstrual cycle), or to treat anestrous (non-
menstruating) females and females with cystic ovaries.”131 
Dairy cows may receive the genetically engineered hormone, 
recombinant bovine somatotropin (rBST), often referred to as 
recombinant bovine growth hormone (rBGH), to increase milk 
production.132  There are no public reports on the use of rBGH in 
dairy production as reporting is not required.  Consumer demand has 
led to a vibrant market for “rBGH free” milk despite a skeptical 
FDA, and labeling rules that generally mandate a disclaimer that 
states that “[n]o significant difference has been shown between milk 
derived from rBST-treated and non-rBST-treated cows.”133 
According to the FDA, “[a]ll of the steroid hormone growth-
promoting drugs are available for over-the-counter purchase in the 
United States and are generally given by the livestock producer at 
specific stages of the animals’ growth.”134  Because these drugs are 
available for direct purchase, and because there are no USDA or 
FDA reporting requirements, the full extent of hormone use in U.S. 
livestock is not known. 
USDA surveys can provide a window into common practices, 
however.  One survey reported that “[a]pproximately 39% of steers 
and heifers weighing less than 700 pounds and 82% of those weighing 
700 pounds or more received at least one hormonal implant in 
1999.”135  Larger livestock operations (8,000 cattle or more) were 
more likely to use hormone implants than smaller operations.136  
Another survey reported that approximately 33% of dairy operations 
used CIDR inserts in 2007.137  A 2007 Dairy Survey reported that 
“rBGH is the most common production enhancement injection used 
 
 130.  CONERLY & CORIANO, supra note 4, at 40. 
 131.  Id.  
 132.  See Interim Guidance on the Voluntary Labeling of Milk and Milk Products From 
Cows That Have Not Been Treated With Recombinant Bovine Somatotropin, 59 Fed. Reg. 
6279, 6279 (Feb. 10, 1994) (stating that lactating dairy cows are given rBST to “increase the 
production of marketable milk”).  
 133.  Id. at 6280.  Note, that the “no significant difference” claim was called into question in 
the case of Int’l Dairy Foods Assoc. v. Boggs, 622 F.3d 628, 637 (6th Cir. 2010).  
 134.  Id.; see also CONERLY & CORIANO, supra note 4, at 39 (stating that natural and 
synthetic hormones are administered to cattle to promote growth).  
 135.  CONERLY & CORIANO, supra note 4, at 40.  
 136.  Id.  
 137.  Id.  
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in dairy operations.”138 
It is impossible to measure the total amounts of hormones 
excreted in the manure produced in the livestock industry.  However, 
one well-regarded estimate indicates that in the year 2000 alone, 
722,852 pounds of estrogens, androgens, and progestogens—not 
including synthetic versions of these hormones—were excreted.139  
Although there is some indication that manure storage prior to land 
application may allow hormones to degrade to inactive levels, 
research indicates that many hormones are active even at low levels 
and can still be considered  endocrine disruptors.140 
C.  Beta-agonists: Ractopamine and Zilmax 
A third category of pharmaceutical, beta agonists, has been 
introduced more recently to the livestock industry.  This category of 
drugs affects animals’ metabolic systems, shifting dietary energy 
toward muscle growth as opposed to fat deposition.141  It promises 
faster growth and faster muscle mass accumulation.142 
Ractopamine is a beta agonist that has been approved for use in 
medicated feed for swine since 1999.143  It was approved for use in 
cattle in 2003144 and turkeys in 2008.145  It is now estimated that 60–
80% of hogs produced in the United States are given ractopamine in 
feed, often in combination with antibiotics such as Tylosin and 
Monensin.146  Its use in turkeys and cattle is thought to be extensive, 
but no public data is available for confirmation.  In 2013, Merck 
estimated that approximately 70% of U.S. beef cattle received either 
 
 138.  Id.   
 139.  Id. at 41.  
 140.  See id. at 45 (“[w]hile hormones are typically detected at low concentrations, such 
chemicals are biologically active at low levels and are classified as endocrine disruptors”).   
 141.  See Donald H. Beerman et al., Council for Agric. Sci. & Tech., Animal Agriculture’s 
Future Though Biotechnology Part 3: Metabolic Modifiers For Use In Animal Production, 30 
ISSUE PAPER 1 (July 2005), available at http://www.cast-science.org/download.cfm?Publication 
ID=2911&File=f0304b7365a7496a189a30694d7f4b617c4f (“[t]hese commercial products 
enhance carcass lean content and feed efficiency”).  
 142.  See id. at 5 (stating that beta agonists stimulate muscle growth).  
 143.  See generally 65 Fed. Reg. 4111 (Jan. 26, 2000) (final rule announcing the approval of 
ractopamine hydrocholoride for use in swine feed and announcing the tolerance level for 
residues of ractopamine in edible tissues of treated swine).  This final rule indicates that the 
drug was approved for use as of December 22, 1999 “for approved feed efficiency and increased 
carcass leaness.”  Id. at 4111. 
 144.   Approved as Optaflexx.  
 145.   Approved as Topmax.  
 146.   See 21 C.F.R. § 558.500 (2014) (listing acceptable combinations of ractopamine, 
Tylosin, and Monensin).   
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Optaflexx, Eli Lilly’s brand of ractopamine in their feed, or Zilmax (a 
competing beta agonist).147 
Ractopamine use is controversial.  All countries in the European 
Union, Russia, Taiwan and China have severely limited or restricted 
ractopamine, citing food safety concerns; although it is allowed in the 
United States, Canada, and Brazil.148  European Union concerns 
include very limited testing of effects on humans and reports of 
adverse human reactions to the drug, including restlessness, anxiety, 
and a fast heart rate.149  The U.S. pork industry, however, argues that 
ractopamine is safe and that countries that have banned its use are 
merely protecting their domestic pork industry.150 
There is no mandatory withdrawal period in the United States 
for ractopamine, meaning animals can receive it up to slaughter with 
a tolerance level expressed as the maximum residue limit (MRLs) of 
50 ppb for pork and 30 ppb for beef.151  In 2012, Codex Alimentarius 
Commission adopted a 10 ppb MRL for both beef and pork.152  A 
2012 study conducted by Consumer Reports tested 240 pork samples 
and found that about 20% of samples were positive for low levels of 
the drug, but the levels were reported to be below both the United 
States and Codex MRLs.153 
Animal welfare concerns have been widely raised.  In 2002, the 
FDA Center for Veterinary Medicine Office of Surveillance and 
Compliance accused Elanco (a division of Eli Lilly) of withholding 
information about reports of “adverse animal drug experiences” and 
the “safety and effectiveness” of the drug.154  A warning label was 
 
 147.   Kelsey Gee, Merck Suspends Sales of Cattle-Feed Additive Zilmax in U.S., Canada, 
WALL ST. J. (Aug. 16, 2013), http://www.wsj.com/articles/SB10001424127887324139 
404579016654038679072.  
 148.    See Helena Bottemiller, FDA Petitioned to Lower Ractopamine Limits for Meat, 
Review Health Impacts, FOOD SAFETY NEWS (Dec. 21, 2012), http://www.foodsafetynews.com/ 
2012/12/fda-petitioned-to-lower-ractopamine-limits-for-meat-review-animal-health-
impact/#.VNeFRFPF-l0 (describing different countries’ approaches to regulating ractopamine).  
 149.  What’s in that pork?, CONSUMER REPORTS MAGAZINE (Jan, 2013) 
http://www.consumerreports.org/cro/magazine/2013/01/what-s-in-that-pork/index.htm.  
 150.  Id.  
 151.  21 U.S.C. § 556.570 (2014).  
 152.  Helena Bottemiller, Codex Adopts Ractopamine Limits for Beef and Pork, FOOD 
SAFETY NEWS (July 6, 2012), http://www.foodsafetynews.com/2012/07/codex-votes-69-67-to-
advance-ractopamine-limits-for-beef-and-pork/#.VPcj0PnF98E. 
 153.  Id.  
 154.  Warning Letter from Gloria J. Dunnavan, Director, Division of Compliance, Center 
for Veterinary Medicine, Office of Surveillance and Compliance, Food and Drug 
Administration, to Patrick C. James, President Elanco Animal Health, A Division of Eli Lilly 
and Company (Sept. 12, 2002) (on file with author).  
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mandated, stating that “Ractomapine may increase the number of 
injured and/or fatigued pigs during marketing.”155 
Opponents claim that ractopamine has been the subject of more 
adverse report incidents in pigs than any other animal drug on the 
market, citing reports to the FDA that include “trembling, lameness, 
inability to walk or rise, reluctance to move, stiffness, hyperactivity, 
hoof disorder, difficulty breathing, collapse, and death.”156  Pigs that 
were administered ractopamine in a research barn squealed when 
they took steps, as if in pain, and refused to leave their pens despite 
proper handling; the pain was even more noticeable when they were 
being shipped.157 
The debate over ractopamine is heightened due to the dramatic 
problems associated with the competing beta agonist, Zilmax, 
manufactured by Merck and approved for use in cattle since 2007.  
Zilmax contains a different active ingredient, zilpaterol 
hydrochloride, and is approved for use in commercial feedlots with a 
withdrawal period of 3 days prior to slaughter.158 
The economic advantages of using Zilmax are enticing to the 
industry.  Merck’s Zilmax website promises gains “from 24 to 33 
pounds of additional carcass weight” per animal.159  Accordingly, 
Merck reported $159 million in Zilmax sales in the United States and 
Canada in 2012.  Estimates are that Zilmax was fed to more than 25 
million cattle.  Significant animal health problems were reported, and 
these reports culminated with the shocking presentation of cattle for 
slaughter at a Tyson Plant in Washington.  “[H]eifers and steers 
hobbled down the ramps on August 5, barely able to walk.  The 
reason: The animals had lost their hooves.”160  The common factor 
among all of the animals was that they had been fed Merck & Co 
Inc’s feed additive, Zilmax.161 
 
 155.  21 C.F.R. 558.500 (2014); see also 67 Fed. Reg. 71,820 (Dec. 3, 2002) (providing notice 
of the new labeling requirement).  
 156.  Complaint at 9, Ctr. for Food Safety et al. v. Margaret A. Hamburg et al., No. 3:14-cv-
4932 (N.D. Cal. Nov. 6, 2014), available at http://www.biologicaldiversity.org/campaigns/ 
toxics_and_endangered_species/pdfs/2014-11-6_Ractopamine_Complaint.pdf. 
 157.  Id.   
 158.  21 C.F.R. § 558.665 (2014).  
 159.  Zilmax Information Center, MERCK, http://www.merck-animal-health-
usa.com/products/zilmax/overview.aspx (last visited Mar. 25, 2015).  
 160.  P.J. Huffstutter & Tom Polansek, Special Report: Lost Hooves, Dead Cattle Before 
Merck Halted Zilmax Sales, REUTERS (Dec. 30, 2013, 5:19 PM), 
http://www.reuters.com/article/2013/12/30/us-zilmax-merck-cattle-special-report-
idUSBRE9BT0NV20131230 [hereinafter Lost Hooves].  
 161.  Id.  
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The day after the hoofless animals were euthanized on August 6, 
Tyson told its feedlot customers it would stop accepting Zilmax-fed 
cattle.  After Reuters reported the existence of a videotape of 
apparently lame Zilmax-fed animals, Merck itself temporarily 
suspended sales of the drug in the United States and Canada.  The 
rest of the nation’s leading meatpackers soon followed Tyson, the 
largest U.S. meat processor.162 
 
The FDA did not take any adverse action with regard to 
Zilmax’s approval status.  Its active ingredient, zipaterol 
hydrocholoride remains an approved animal drug for use in feed,163 
and Zilmax’s new drug application and approval is still available on 
the FDA’s website per its prior approval.164  Merck is currently 
seeking to re-launch Zilmax at a lower dosage.165  The FDA approved 
Merck’s Supplemental New Drug Application in October 2014 
providing for a lower dosage of Zilmax to be sold for use in cattle fed 
in confinement for slaughter.166  Merck is currently working to 
convince a still-skeptical beef industry that it should resume use.167  
Meanwhile, use of competing ractopamine products in the cattle 
 
 162.  Id.; see also, Kelsey Gee, Merck Suspends Sales of Cattle-Feed Additive Zilmax in U.S., 
Canada, WALL ST. J. (Aug. 16, 2013, 12:01 PM), http://www.wsj.com/articles/SB100014 
24127887324139404579016654038679072 (detailing Merck’s decision to suspend its sales of feed 
with the Zilmax additive).  
 163.  21 C.F.R. § 558.665 (2014).  
 164.   FOOD & DRUG ADMIN., FREEDOM OF INFORMATION SUMMARY, ORIGINAL NEW 
ANIMAL DRUG APPLICATION NADA 141-258 41 (2006) (approving Zilmax as “safe and 
effective”); see also ZILMAX, http://www.zilmax.com (last visited Feb. 24, 2015) (stating that 
“Zilmax is an FDA-approved feed supplement.”).  
 165.  P.J. Huffstutter & Tom Polansek, Exclusive: Merck Funds Tests of Lower Zilmax 
Doses As Seen Seeking Way to Resume Sales, REUTERS (Jan. 19, 2015, 8:02 AM), http://www. 
reuters.com/article/2015/01/19/us-merck-co-zilmax-idUSKBN0KS18020150119 [hereinafter 
Merck Funds].  
 166.  FOOD & DRUG ADMIN., FREEDOM OF INFORMATION SUMMARY, SUPPLEMENTAL 
NEW ANIMAL DRUG APPLICATION NADA 141-258 (2014), available at 
http://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FO
IADrugSummaries/UCM421907.pdf (requiring adding the statement “CAUTION: Not to be 
fed to cattle in excess of 90 mg/head/day”).  
 167.  See Merck Funds, supra note 165(describing Merck’s efforts to resume sales of 
Zilmax); see also Dan Charles, Beef Packers Block Plan To Revive Growth-Promoting Drug, 
NATIONAL PUBLIC RADIO: THE SALT (Jan. 27, 2015, 11:30 AM), 
http://www.npr.org/blogs/thesalt/2015/01/27/381630528/beef-packers-block-plan-to-revive-
growth-promoting-drug (stating that Merck has been working on a plan to revive th  use of 
Zilmax).  
11-Schneider_Final (Do Not Delete) 8/17/2015  5:20 PM 
252 DUKE ENVIRONMENTAL LAW & POLICY FORUM [Vol. XXV:227 
industry has soared.168 
Little is known about the exact amount of beta agonists that are 
released into the environment from their use in the livestock industry, 
or about their potential impact.  As an example of an industry 
assessment, in 1998 Elanco prepared an Environmental Assessment 
(EA) in conjunction with their application for approval of their 
ractopamine product for cattle.169  This assessment confirms that the 
drug has the potential to impact the area surrounding the mixing 
facilities; the feedlot area and its surroundings; agricultural lands 
where manure is applied; and aquatic systems receiving runoff from 
animal waste storage.170  The EA grossly underestimates the actual 
use of the drug, however, by referencing an “optimistic market 
penetration rate of 35 percent.”171  Actual market penetration is now 
estimated to be between 60–80%.172  The EA also describes a “typical 
feedlot” as one housing 200 cows, when today’s feedlots typically hold 
1,000-100,000 cattle at a time.173  In addition, the EA fails to consider 
the cumulative impact of use in multiple species.174  By some 
estimates, “the combined population of ractopamine-drugged pigs, 
cattle, and turkeys may excrete over a million pounds of the drug.”175  
The EA also fails to consider the impact of multiple drugs released 
into the system as a result of competing drugs (e.g., ractopamine and 
Zilmax). 
D.  Environmental Effects 
The potential dangers of animal drugs in manure has already 
been realized in the case of arsenic.  Despite decades of prohibition of 
 
 168.  See Jesse Newman, Merck Pushes to Revive Beef Drug, WALL ST. J. (July 14, 2014, 7:32 
PM), http://www.wsj.com/articles/merck-pushes-to-revive-beef-drug-1405380749 (describing two 
competitors’ entrance into the growth-promoting drug market).  
 169.  ELANCO ANIMAL HEALTH, ENVIRONMENTAL ASSESSMENT FOR THE USE OF 
RACTOPAMINE HYDROCHLORIDE PREMIX IN THE FEED OF CATTLE (1998), available at 
http://www.fda.gov/downloads/AnimalVeterinary/DevelopmentApprovalProcess/Environmenta
lAssessments/UCM303565.pdf.  
 170.  See id. at 5 (describing potential environmental impacts of the drug). 
 171.  Id. at 9.  
 172.  Complaint for Declaratory and Injunctive Relief at 16, Humane Soc’y of the U.S. v. 
Hamburg, No. 3:14-cv-04933 (N.D. Cal. Nov. 6, 2014); Complaint, Ctr. for Food Safety, No. 3:14-
cv-4932 at 8 
 173.   ELANCO, supra note 169.  
 174.   See supra notes 79–81 and accompanying text. 
 175.   Complaint, Humane Soc’y of the U.S., No. 3:14-cv-04933 at 16; see also Complaint, Ctr. 
for Food Safety, No. 3:14-cv-4932  at 11, (“[a]lmost all ractopamine fed to cattle, pigs, and turkey 
is excreted into their manure.”).  
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the use of arsenicals as pesticides by the EPA, the FDA continued to 
allow the arsenical roxarsone in poultry production.176  It was used to 
promote rapid growth, increased weight gain, and improved feed 
efficiency.177  A report estimated that in 2006, the vast majority of the 
broiler chickens produced in the United States were given feed 
containing arsenic compounds at some point in their lives.178  
Although no public data is available, estimates suggest that over 2 
million pounds of roxarsone was given to chickens annually.179 
Consumer concerns led to industry pulling back on its use,180 and the 
production of roxarsone was suspended following a 2011 FDA finding 
of traces of inorganic arsenic in poultry tissue.181  However, beyond 
the direct food safety issue associated with chicken products, arsenic 
has been found in poultry feathers, poultry bedding, and in the 
manure that is spread on cropland—contributing to high levels of 
arsenic in rice produced on that land.182 
As evidenced by the problems with the arsenic use in poultry 
production, there is a persuasive argument that each of the categories 
of pharmaceuticals used in the livestock industry—antimicrobials, 
hormones, beta agonists, and others not addressed in this article—
 
 176.   See Susan A. Schneider, Examining Food Safety From a Food Systems Perspective: 
The Need for a Holistic Approach, 2014 WISC. L. REV. 397 (2014) (“[t]he FDA’s approval led to 
the widespread use of roxarsone”).  
 177.   New Animal Drugs for Use in Animal Feeds: Roxarsone, 46 Fed. Reg. 52,330, 52,331 
(Oct. 27, 1981) (affecting 21 CFR 558). [46 FR 52330-02]  
 178.   DAVID WALLINGA, INST. FOR AGRIC. & TRADE POL’Y, PLAYING CHICKEN: 
AVOIDING ARSENIC IN YOUR MEAT 13 (2006), available at http://www.iatp.org/files/ 
421_2_80529.pdf.  
 179.   Id.  
 180.   It was reported that Tyson Foods stopped using arsenicals in its chickens in 2004. 
Marian Burros, Chicken with Arsenic? Is That O.K.?, N.Y. TIMES (Apr. 5, 2006), 
http://www.nytimes.com/2006/04/05/dining/05well.html.  Perdue said it stopped using arsenicals 
in 2007. Darryl Fears, Maryland Set To Ban Arsenic-Containing Drug in Chicken Feed, WASH. 
POST (May 20, 2012), http://www.washingtonpost.com/national/health-science/maryland-set-to-
ban-arsenic-containing-drug-in-chicken-feed/2012/05/20/gIQAFoIodU_story.html. 
 181.  See Letter from Michael Taylor, Deputy Comm’r for Foods & Veterinary Medicine, to 
Paige M. Tomaselli, Staff Attorney, Ctr. for Food Safety, and David Wallinga, Director, Food & 
Health Division of Inst. for Agr. and Trade Pol’y 5 (Sept. 30, 2013), available at 
http://www.fda.gov/downloads/AnimalVeterinary/SafetyHealth/ProductSafetyInformation/UC
M370570.pdf (denying the Center for Food Safety petition).  
 182.  See Susan A. Schneider, Examining Food Safety From a Food Systems Perspective: The 
Need for a Holistic Approach,  2014 WISC. L. REV. 397 (2014) (citing Fu-Min Wang, Zhang-Liu 
Chen, Lu Zhang, Yan-Ling Gao, & Yong-Xue Sun, Arsenic Uptake and Accumulation in Rice 
(Oryza sativa L.) at Different Growth Stages Following Soil Incorporation of Roxarsone and 
Arsanilic Acid, 285 PLANT & SOIL 359 (July 2006) (concluding that rice could accumulate 
arsenic “from contaminated soil (roxarsone or arsanilic acid), which may be transferred to 
human beings via the food chain”)).  
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should be more carefully reviewed for the environmental impacts 
associated with their use.  Numerous scientific studies performed on 
each of the individual categories and/or on individual pharmaceuticals 
support this argument.183  Adverse environmental impacts are not 
being adequately considered in our evaluation and approval of the 
use of these drugs.184 
There is an even more persuasive argument that we have no 
concept, indeed no way to adequately measure, the cumulative 
impact of the millions of pounds of different drugs used in the 
livestock industry.  Much of those drugs are then excreted in the 1.1 
billion tons of manure produced each year. 
IV. THE REGULATION OF DRUGS ADMINISTERED TO LIVESTOCK 
The United States Department of Agriculture is the federal 
agency involved in most matters involving livestock production, 
including the prevention of livestock disease185 and the regulation of 
livestock markets.186  The USDA is also responsible for the labeling 
and safety regulations applicable to most meat products.187  
Nevertheless, as described below, the regulation of animal drugs is 
controlled by the FDA. 
A. The Regulation of Animal Drugs Under the Food, Drug, and 
Cosmetic Act 
The Food, Drug, and Cosmetic Act (FDCA) governs the 
approval of animal drugs and gives regulatory authority to the 
Secretary of the Department of Health and Human Services (HHS).188  
 
 183.  See, e.g., Alistair B. A. Boxall et al., Are Veterinary Medicines Causing Environmental 
Risks?, 37 ENVTL. SCI. & TECH. 286A (2003) (discussing the likelihood of various veterinary 
medicines entering into the environment, and concluding that “too little is known about the 
effects of these compounds”). 
 184.  CONERLY & CORIANO, supra note 4, at v–vi (stating that environmental impacts of 
antimicrobial use in livestock are “poorly understood,” and “would benefit from further 
research”).  
 185.  The USDA Animal & Plant Health Inspection Service (APHIS) “works in a variety of 
ways to protect and improve the health, quality, and marketability of our nation's animals 
(including various wildlife), animal products, and veterinary biologics.”  U.S. DEP’T OF AGRIC., 
Animal & Plant Health Inspection Serv., http://www.aphis.usda.gov/wps/portal/ 
aphis/ourfocus/animalhealth (last visited Feb. 24, 2015). 
 186.  The USDA administers the Packers and Stockyards Act, 7 U.S.C. §§ 181–229b (2012), 
through the Grain Inspection and Packers and Stockyards Administration (GIPSA).  
 187.  The USDA Food Safety and Inspection Service (FSIS) is responsible for meat 
regulation as authorized under the Federal Meat Inspection Act, 21 U.S.C. §§ 601–695 (2012), 
and the Poultry Products Inspection Act, 21 U.S.C. §§ 451–472.  
 188.  The definition of “drug” contained in the statute includes “articles intended for use in 
11-Schneider_Final (Do Not Delete) 8/17/2015  5:20 PM 
Spring 2015] BEYOND THE FOOD WE EAT 255 
The Secretary has delegated this authority to the Commissioner of 
the Food and Drug Administration (FDA).189  The statute provides 
that a new animal drug “shall be deemed unsafe” unless the 
manufacturer has obtained FDA “approval,” a “conditional 
approval,” or an allowed “index listing” of the drug for use in “minor 
species.”190  Animal feed that contains a new animal drug is similarly 
regulated.191 
The phrase “new animal drug” is broadly defined and extends far 
beyond the literal creation of a new drug.  The FDCA states that 
“[t]he term ‘new animal drug’ means any drug intended for use for 
animals other than man.”192  The regulations clarify that it includes all 
new uses for existing drugs, new combinations of drugs, the use of the 
drug in a new species, and other changes in usage, composition, or 
labeling.193 
The approval process for any new animal drug is outlined in 
FDCA section 360b(b).  The drug’s sponsor is required to submit an 
application that includes “full reports of investigations which have 
been made to show whether or not such drug is safe and effective for 
use.”194  According to the statute, the application must also include a 
“full statement of the composition” of the drug; a description of the 
manufacturing process; samples of the drug, the feed it might be used 
in, and edible portions of the animal to which it will be given (“as the 
Secretary may require”); examples of the proposed labeling; a 
description of the “practicable methods for determining the quantity, 
if any, of such drug in or on food . . . because of its use;” and the 
“proposed tolerance level or withdrawal period or other use 
restrictions” necessary to render the drug’s use “safe.”195 
There are special provisions in the statute that exempt the 
 
the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals; and 
articles (other than food) intended to affect the structure or any function of the body of man or 
other animals.”  21 U.S.C. § 321(g)(1)(B)–(C) (emphasis added).  
 189.  FOOD & DRUG ADMIN., FDA STAFF MANUAL GUIDES, VOLUME II—DELEGATIONS 
OF AUTHORITY: REGULATORY DELEGATIONS OF AUTHORITY TO THE COMMISSIONER FOOD 
AND DRUGS 1 (2014), available at http://www.fda.gov/downloads/AboutFDA/ReportsManuals 
Forms/StaffManualGuides/UCM273771.pdf.  
 190.  21 U.S.C. § 360b(a)(1)(A)–(C) (2012).  
 191.  See 21 U.S.C. § 360b(a)(2)(A)(i)–(iii) (deeming animal feed containing new animal 
drugs unsafe unless granted an approval, a conditioned approval, or an index listing).  
 192.  21 U.S.C. § 321(v) (2012).  
 193.  21 C.F.R. § 510.3(i) (2007).  
 194.  21 U.S.C. § 360b(b)(1).  
 195.  Id.  
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“investigational use” of drugs from this process.196  For some drugs, a 
more streamlined process exists, using an “abbreviated application.”197  
An abbreviated application is appropriate if there has been a drug 
with the same active ingredients approved previously for the same 
use.198 
Support for the pharmaceutical and agricultural industries is 
conspicuous throughout section 360b.  Although drugs may be 
considered unsafe if they do not comply with the defined approval 
processes, the section includes numerous directives that prohibit the 
agency from finding a drug unsafe.199  Indeed, the latest amendment to 
section 360b and the animal drug review process, in general, was 
passed as the Animal Drug Availability Act.200  The Congressional 
findings contained in this bill when it was first proposed, provide an 
informative window into Congressional attitudes about drug use in 
the livestock industry.  The findings are as follows: 
 
Congress finds that— 
(1) the new animal drug approval process has been 
proceeding too slowly, with the result that necessary and useful 
drug therapies are being kept from the marketplace; 
(2) the lack of drug approvals for new animal drugs places the 
health and well-being of animals at risk; 
(3) the expense and delays caused by effectiveness testing for 
new animal drugs have begun to outweigh the benefits of such 
testing; 
(4) the overreliance on field investigations to establish the 
effectiveness of new animal drugs is a primary reason the new 
animal drug approval process has become so burdensome; 
(5) there are not sufficient approved animal drugs available to 
treat every specific disease or condition found in each species of 
animal; 
(6) it would benefit the public health and safety to have many 
additional animal drugs reviewed and approved by the Food and 
 
 196.  21 U.S.C. §§ 360b(a)(3), (j).  
 197.  21 U.S.C. § 360b(b)(2). The requirements for approval under the abbreviated process 
are set forth in 21 U.S.C. § 360b(n).  
 198.  21 U.S.C. § 360b(n)(1)(B)(i). 
 199.  See, e.g., 21 U.S.C. § 360b(a)(4)–(6) (prohibiting the agency from finding an animal 
drug unsafe for specified reasons). 
 200.  The Animal Drug Availability Act of 1996, Pub. L. No. 104-250, 110 Stat. 3151 
(codified as amended at 21 U.S.C. §§ 301, 331, 353, 354, 360b (2012)).  
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Drug Administration; 
(7) economic and regulatory incentives are necessary to 
encourage manufacturers of animal drugs to convert unlabeled 
uses of the drugs to approved, labeled uses; and 
(8) it is important that the Center for Veterinary Medicine of 
the Food and Drug Administration promptly implement the 
recently developed mission, vision, and guiding principles of the 
Center so that the Food and Drug Administration is a global leader 
as a public health organization that enables the marketing of safe 
and effective products.201 
 
These findings clearly reflect Congress’ interest in expanding the 
use of animal drugs in the livestock industry, although it rather 
curiously justifies this interest as furthering the “the health and well-
being of animals” and “public health and safety.”202  By 1995, when 
these findings were reported, public health officials worldwide were 
expressing serious concerns about the adverse public health 
consequences associated with the overuse of antibiotics in the 
livestock industry.203  Congress’s motivations were likely expressed 
more honestly in earlier findings: 
 
In the past 15 years the animal feed industry in the United States 
has been virtually revolutionized through the use of drugs and 
other additives in the feed of animals.  Drugs are used to promote 
growth and combat disease, and as a result of the increasing use, 
animals today add more meat per pound to feed in a much shorter 
time than has ever been true in the past.204 
 
Congress recognized that the livestock industry had become 
dependent on using animal drugs to lower production costs.  This 
factor places new animal drugs in sharp contrast to human drugs.  For 
individuals suffering from a disease or other medical condition, the 
rapid approval of a new drug to treat that condition, provided that the 
drug is safe, may have a dramatic and positive impact on public 
health.  Streamlining the approval process can be justified for 
 
 201.  S. 773, 104th Cong. § 2 (1995), available at https://www.congress.gov/104/bills/s773/ 
BILLS-104s773is.pdf.  
 202.  See id. (expressing a desire to expedite and expand the approval process, and 
identifying animal health and well-being and public health and safety as motivating factors). 
 203.  For a listing of such studies, see JUDICIOUS USE, supra note 100, at 5–17.  
 204.  H.R. REP. NO. 90-875, at 2 (1967).  
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humanitarian reasons, provided it remains safe.  In contrast, the 
purpose of many new animal drugs is not to treat disease but to 
reduce production costs. This reduction may occur through increased 
feed conversion rates or through prophylactic use to allow for 
increased concentration without increasing disease rates.  These are 
economic objectives, not public health objectives, and certainly not 
animal welfare objectives.  Thus, they do not deserve the same 
treatment. 
Despite Congress’ interest in streamlining the approval of new 
animal drugs, the statute does require a showing that a new animal 
drug be “safe and effective.”205  Effectiveness refers to whether the 
drug works as promised.206  The FDCA defines “safe” as having 
“reference to the health of man or animal.”207 
The notion of new animal drug safety in terms of the health of 
the animal sits awkwardly next to competing economic 
considerations. Many of the drugs approved are not good for the 
animals’ health, particularly in the long run.208  Rapid growth, 
increased milk and egg production and related goals often run 
completely counter to the animals’ long-term health.209  For meat 
producing animals, a shorter life span may actually be the economic 
production goal associated with the drug.  For example, steroids are 
given with the express purpose of increasing the growth rate of the 
animal.210  In an animal raised for slaughter, this means an earlier 
death.  For product-producing animals such as dairy cows and 
chickens raised for egg production, the shorter period of production 
may be outweighed economically by increased output early in life.211 
 
 205.  21 U.S.C. § 360b(b)(1)(A) (2012).  
 206.  21 C.F.R. § 514.4(a) (2014).  
 207.  21 U.S.C. § 301(u) (2012).  
 208.   See, e.g., supra footnotes 159–176 and accompanying text (animal well being problems 
resulting from the use of Zilmax (noting severe health problems associated with the use of the 
drug)). 
 209.  See, e.g., HUMANE SOC’Y OF THE U. S., AN HSUS REPORT: WELFARE ISSUES WITH 
SELECTIVE BREEDING FOR RAPID GROWTH IN BROILER CHICKENS AND TURKEYS 2–3 (May 
2014), available at http://www.humanesociety.org/assets/pdfs/farm/welfiss_breeding_ 
chickens_turkeys.pdf (describing the adverse health impact of rapid growth in poultry 
production and providing an extensive bibliography of animal welfare research); HUMANE 
SOC’Y INT'L, AN HSI REPORT: THE WELFARE OF ANIMALS IN THE PIG INDUSTRY 6 (2014), 
available at http://www.hsi.org/assets/pdfs/hsi-fa-white-papers/welfare_of_animals_in_the_ 
pig.pdf (describing animal health problems associated with industrialized hog production and 
feed additives and providing an extensive bibliography of animal welfare research).  
 210.  Steroid Hormone Implants, supra note 123.   
 211.   For example, cows that are treated with the hormone Bovine Somatotropin (rBST) 
produce more milk during peak production periods, but have other health problems including 
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In determining whether the livestock drug is safe with “reference 
to the health of man” the statute calls for a consideration of (1) 
whether there will be drug residues found in a human food product, 
and (2) if so, what level of those residues FDA determines will be 
safe.212  Approval will likely involve setting a “tolerance” for the drug, 
i.e., an allowed amount of drug residue found in the human food 
products obtained from the animal that has received the drug.213  
Human exposure via the environment is not mentioned. 
The drug may also be approved subject to a mandatory 
“withdrawal period.”214  The withdrawal period is the period of time 
that the drug cannot be used in order to assure compliance with the 
set tolerance for the drug residue.215  For animals marketed for meat, 
the withdrawal period references the time before slaughter.216  For 
other food products such as milk and eggs, it references the period of 
time required between drug use and the marketing of any product 
from the animal for human consumption.217 
Note that the tolerances set for various drugs are correlated with 
average consumption patterns.  If daily consumption values for the 
meat decline, the FDA can and has raised the tolerances allowed.218  
 
mastitis and lameness. See generally I. R. Dohoo et. al., A Meta-Analysis Review Of The Effects 
Of Recombinant Bovine Somatotropin, 67 CAN. J. VET. RES. 252 (2003), available at 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC280709/ (presenting a meta-analysis of the effects 
of rBST on various aspects of bovine health). Nonetheless, this hormone is considered safe with 
reference to the animal receiving the drug.  See FOOD & DRUG ADMIN., Bovine Somatotropin 
(BST), http://www.fda.gov/animalveterinary/safetyhealth/productsafetyinformation/ucm0554 
35.htm (last updated July 28, 2014).  
 212.  21 U.S.C. § 360b(a)(6) (2012); see also, 21 U.S.C. § 360b(d)(1)(F) (allowing rejection of 
any drug with a residue beyond the determined safe tolerance level).  
 213.  21 U.S.C. § 360b(a)(6); 21 C.F.R. § 556 (2014).  
 214.  21 U.S.C. § 360b(b)(1)(H); 21 C.F.R. § 514.105(a) (2014). 
 215.  Withdrawal periods are established as part of the new drug approval process and are 
published on the drug or feed label or package insert. See, 21 U.S.C. § 360b(b)(1) (requiring 
person to submit the proposed withdrawal period if it is required to ensure that the proposed 
use of such drug will be safe); 21 C.F.R. § 514.105 (requiring the Commissioner to forward for 
publication in the Federal Register a regulation prescribing the conditions for the new animal 
drug including the withdrawal period).  For a helpful explanation, What are Withdrawal Times 
(Periods) for Meat and Milk, and Where Can They be Found?, EXTENSION FOUND. (Sept. 6, 
2007), http://www.extension.org/pages/35903/what-are-withdrawal-times-periods-for-meat-and-
milk-and-where-can-they-be-found#.VPOm72PYR8w. 
 216.  What are Withdrawal Times (Periods) for Meat and Milk, and Where Can They be 
Found?, EXTENSION FOUND. (Sept. 6, 2007), http://www.extension.org/pages/35903/what-are-
withdrawal-times-periods-for-meat-and-milk-and-where-can-they-be-found#.VPOm72PYR8w.  
 217.  Id.  
 218.  See, e.g., 76 Fed. Reg. 57,907 (Sept. 19, 2011) (to be codified at 21 C.F.R. § 556.540) 
(raising the tolerance for progesterone in beef and lamb).  The notice states that  “Progesterone 
is approved for use in subcutaneous implants used for increased rate of weight gain in suckling 
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Alarmingly, there does not seem to be any practicable way for the 
FDA to consider the variety of drug residues that an individual might 
consume from different sources. 
Section 360b authorizes the FDA to withdraw its approval of a 
new animal drug “after due notice and an opportunity for hearing” if 
certain conditions are met.  There are six possible grounds for 
withdrawal: 
(1) “Experience or scientific data” shows that the drug is “unsafe 
for use” under the conditions for which it was approved; 
(2) “New evidence not contained in [the] application or not 
available” to the agency, evaluated with the prior evidence 
shows that the drug is “not shown to be safe;” 
(3) On the basis of new information, together with prior 
evidence, there is a “lack of substantial evidence” that the 
drug will have “the effect it purports or is represented to 
have;” 
(4) Required patent information is not filed; 
(5) The application is found to have contained an “untrue 
statement of a material fact;” 
(6) The applicant has made changes affecting safety or 
effectiveness beyond allowed variations and not addressed in 
a supplemental application.219 
There is also a provision that allows withdrawal—after due 
notice and opportunity for a hearing—in cases where an applicant has 
failed to comply with recordkeeping requirements, new evidence of 
manufacturing problems are revealed, or new evidence of false 
labeling is discovered.220 
There is also authority for an immediate suspension of approval, 
but this authority is limited to the Secretary (or acting Secretary) of 
Health and Human Services.  Immediate suspension requires a 
showing of an “imminent hazard to the health of man or of the 
animals for which the drug is intended.”221  The applicant may request 
 
beef calves and steers (21 CFR 522.1940) and in vaginal inserts used for management of the 
estrous cycle in female cattle and ewes (21 CFR 529.1940)”; see also Susan A. Schneider, 
Hormone Levels in Beef and Lamb: Does Anyone Care, AGRIC. L. (Oct. 15, 2011), 
http://aglaw.blogspot.com/2011/10/hormone-levels-in-beef-and-lamb-does.html (expressing 
concern and surprise about the increased tolerance level for progesterone in beef and lamb).  
 219.  21 U.S.C. § 360b(e)(1)(A)–(F) (2012). 
 220.  21 U.S.C. § 360b(e)(2)(A)–(C).  
 221.  21 U.S.C. § 360b(e)(1).  
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an expedited hearing.222 
Despite these withdrawal and suspension authorities, the FDA 
has used its power sparingly, often preferring to let industry forces 
come to bear, as with Zilmax.223  Alternatively, FDA will use its 
efforts to nudge the industry via guidances and voluntary 
recommendations.224   
The “due process and notice of hearing” requirement associated 
with withdrawal of an application may well extend to litigation 
brought by a drug manufacturer that seeks to fight the withdrawal 
efforts.  The FDA has argued that it can be more effective, produce 
results more quickly, and expend fewer resources by working 
collaboratively with industry.225  This position, however, and agency’s 
inaction in the face of controversial drugs, has prompted third parties 
to litigate in order to force withdrawal.  The case of Natural 
Resources Defense Council, Inc. v. FDA,226 discussed below, serves as 
one prominent example. 
B.  Increased Concern Over the Regulation of Antibiotics: Regulation, 
Litigation, and “Judicious Use” 
As already noted, there is widespread concern among health 
professionals about the development of antibiotic resistant pathogens.  
The extensive use of antibiotics in livestock production, particularly 
of antibiotics that are important for human use, has been well 
established as a contributing factor.  “For over thirty years the FDA 
has taken the position that the widespread use of certain antibiotics in 
livestock for purposes other than disease treatment poses a threat to 
 
 222.  Id.  
 223.  See supra note 162 and accompanying text (describing the process through which 
Zilmax, an FDA-approved beta agonist, was largely boycotted by the beef industry after severe 
animal health problems were discovered).  
 224.  For a current example of this approach, see infra notes 254–265 and the accompanying 
text: JUDICIOUS USE, supra note 101 (attempting to convince the industry to voluntarily reduce 
the use of medically important antimicrobials by explaining its concern); see also Richard A. 
Merrill, Risk-Benefit Decisionmaking by the Food and Drug Administration, 45 GEO. WASH. L. 
REV. 994, 1002 (1977) (explaining common criticisms that the FDA gives too much weight to 
industry interests in its drug approval process). 
 225.  E.g., FOOD & DRUG ADMIN., REPORT ON GOOD GUIDANCE PRACTICES: IMPROVING 
EFFICIENCY AND TRANSPARENCY (2011), available at http://www.fda.gov/downloads/ 
AboutFDA/Transparency/TransparencyInitiative/UCM285124.pdf (detailing ways in which the 
FDA can increase its efficiency and transparency, including making guidance documents and 
recommendations more easily accessible).  
 226.  Natural Res. Def. Council, Inc. v. FDA, 884 F. Supp. 2d 127 (S.D.N.Y. 2012) 
[hereinafter Natural Res. Def. Council I].  
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human health.”227 
In 1977, the FDA acted on this position, issuing notices of 
withdrawal under section 360b(e)(1)(B), seeking to withdraw 
approval of all subtherapeutic uses of penicillin in animal feed, and 
with limited exceptions, all subtherapeutic uses of oxytetracycline and 
chlortetracycline in animal feed.228  Following the statutory 
procedures for withdrawal, the notices extended the opportunity for a 
hearing (NOOHs) to every drug manufacturer affected.229  What 
followed is over thirty years of industry lobbying, Congressional 
interference, agency inaction, and eventually litigation—all giving rise 
to the FDA’s current policy of “judicious use.”230 
Soon after the NOOHs were issued, Congress directed funds to 
the National Academies of Sciences so it could conduct further 
research on the use of antibiotics in animal feed.231  “The report issued 
by the House Appropriations Committee included thinly veiled 
suggestions that the FDA not go forward with the hearing process 
until the research was completed.”232  Two years later, Congress again 
expressed its interest in funding additional studies and its 
discouragement of FDA action until greater certainty was 
established.233 
Industry groups concurrently petitioned the FDA to withdraw 
the NOOHs, but in 1983, the FDA denied their petitions and 
reaffirmed its concerns.234  Additional studies were conducted, 
producing evidence of expanding antibiotic resistance and increasing 
concerns about livestock production, but without specifically 
providing a direct causal link between specific agricultural use and the 
 
 227.  Id. at 130.  
 228.  Penicillin-Containing Premixes: Opportunity for Hearing, 42 Fed. Reg. 43,772 (Aug. 
30, 1977); Tetracycline (Chlortetracycline and Oxytetracycline) Containing Premixes: 
Opportunity for Hearing, 42 Fed. Reg. 56,264, 56,266 (Oct. 21, 1977).  
 229.  Id. 
 230.  See Withdrawal of Notices of Opportunity for a Hearing: Penicillin and Tetracycline 
Used in Animal Feed, 76 Fed. Reg. 79,697, 79,698 (Dec. 22, 2011) (recapping the FDA’s 1977 
actions to withdraw uses of penicillin and tetracycline in animal feed and expressing the FDA’s 
new 2011 plan to focus its energy on “the promotion of the judicious use of antimicrobials in the 
interest of public health”).  
 231.  Natural Res. Def. Council, Inc. v. FDA, 760 F.3d 151, 154 (2d Cir. 2014) [hereinafter 
Natural Res. Def. Council II].  
 232.  Id. (citing H.R. REP. NO. 95-1290, at 99 (1978)).  
 233.  Id. at 155 (citing S. REP. NO. 97-248, at 79 (1981)).  
 234.  Id. (citing Penicillin and Tetracycline (Chlortetracycline and Oxytetracycline) in 
Animal Feeds; Denial of Petitions, 48 Fed. Reg. 4544, 4556 (Feb. 1, 1983)).  
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specific antibiotic resistance observed.235  The FDA never held the 
hearings and never took any further action in its efforts to withdraw 
the drugs noticed. 236 
In 1999 and again in 2005, public interest groups filed petitions 
with the FDA seeking withdrawal of regulatory approval for 
subtherapeutic livestock use of specified antibiotics, including 
penicillin and tetracyclines.237  The FDA was still not compelled to 
act.238 
In 2011, the National Resources Defense Council, with other 
public interest organizations initiated suit.239  Their primary claim was 
that section 360b(e)(1) “compelled the FDA to hold the hearing 
proposed by the 1977 NOOHs and, if appropriate, withdraw approval 
for the antibiotic uses the NOOHs listed.”240  The FDA defended 
vigorously, arguing that an alternative approach would be more 
effective than seeking withdrawal. The agency alleged that the 
process that was required to withdraw approval of a drug is lengthy 
and costly. They also alleged that new scientific findings would be 
required and that they would be forced proceed on a drug-by-drug 
basis.  Accordingly, the FDA argued that the alternative course of 
action, pursuing voluntary measures, was preferable.241 
In December 2011, the FDA formally withdrew the 1977 
NOOHs.242  The plaintiffs amended their complaint and moved 
forward.243  The district court ruled in the plaintiffs’ favor, holding that 
section 360b(e) “requires the Secretary to issue notice and an 
opportunity for a hearing whenever he finds that a new animal drug is 
not shown to be safe.  If the drug sponsor does not meet his burden of 
demonstrating that the drug is safe at the hearing, the Secretary must 
issue an order withdrawing approval of the drug.”244  The district court 
found that the FDA’s issuance of the NOOHs in 1977 constituted a 
finding that that drugs were not shown to be safe.245  It ordered FDA 
 
 235.  Natural Res. Def. Council II, 760 F.3d at 155.  
 236.  Id.  at 155–56.  
 237.  Id.  
 238.  Id. at 156.  
 239.  Id.  
 240.  Id.  
 241.  Id. at 156–57.  
 242.  Withdrawal of Notices of Opportunity for a Hearing: Penicillin and Tetracycline Used 
in Animal Feed, 76 Fed. Reg. 79,697 (Dec. 22, 2011).  
 243.  Natural Res. Def. Council II, 760 F.3d at 157.  
 244.  Natural Res. Def. Council I, 884 F. Supp. 2d at 143.   
 245.  Id. at 151.  
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to conduct withdrawal hearings and, unless the manufacturers could 
rebut the finding, withdraw approval for those drug uses.246 
The FDA appealed the decision, and the Court of Appeals for 
the Second Circuit deferred to the agency’s interpretation of the 
statute and reversed.247  The Second Circuit held that the district court 
erred in its reading of section 360b and that the NOOHs that were 
issued did not constitute a finding that mandated agency action.248  
The majority opinion of the Second Circuit Court provides: 
 
The statute requires the FDA to withdraw approval of an animal 
drug only ‘after due notice and opportunity for hearing’ has been 
afforded, and then only ‘if the Secretary finds’ that the drug is not 
shown to be safe.  21 U.S.C. § 360B(e)(1).  That language most 
naturally refers to a finding that is issued as a result of the 
hearing.249 
 
There is a good deal of irony in this litigation.  The FDA has 
argued against the widespread use of subtherapeutic antibiotics in the 
livestock industry for “over thirty years.”250  The plaintiffs shared the 
FDA’s concerns about their use.  Nevertheless, the FDA argued that 
the withdrawal process would expend resources and result in costly 
litigation.251  Yet, in resisting the plaintiff’s complaint, it ended up 
litigating with groups that share its concerns.  In the end, it won the 
right to not take action.252  Needless to say, this should be an 
unsatisfying victory in many respects. 
In the midst of the litigation, the FDA issued a guidance for 
industry that articulated its recommended principles for the use of 
antibiotics in livestock production.253  This guidance is an embodiment 
of the FDA’s preferred strategy—to work with the industry and guide 
it to a better position rather than pursuing withdrawal.  It is a non-
binding statement of the FDA’s favored approach to regulating the 
agricultural use of antibiotics considered to be medically important to 
 
 246.  Id. at 151–52.  
 247.  Natural Res. Def. Council II, 760 F.3d at 176.  
 248.  Id. at 174.  
 249.  Id. at 172. 
 250.  Natural Res. Def. Council I, 884 F. Supp. 2d at 130.  
 251.  Natural Res. Def. Council II, 760 F.3d at 156–57.  
 252.  Natural Res. Def. Council II, 760 F.3d at 176.  
 253.  See generally JUDICIOUS USE, supra 100 (providing guidance on the FDA’s current 
thinking on this topic).  
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humans.254 
The guidance begins with an extensive description of the history 
of studies and reports documenting public health concerns with 
antibiotic resistance.  The guidance then discusses the indirect, but 
conclusively established, connection between the extensive use of 
medically important antibiotics in livestock production and the 
increasing resistance observed.255  It is an impressive argument against 
the use of antibiotics important to human health in livestock 
production. 
The guidance also sets forth the FDA’s two main principles for 
what it terms the “Judicious Use” of antibiotics: 
 
Principle 1: The use of medically important antimicrobial 
drugs in food-producing animals should be limited to those uses 
that are considered necessary for assuring animal health. 
Principle 2: The use of medically important antimicrobial 
drugs in food-producing animals should be limited to those uses 
that include veterinary oversight or consultation.256 
 
There are several weaknesses associated with the FDA’s 
approach.  First, given the financial interests at stake, the competition 
in both the livestock and the pharmaceutical industries, and the 
decades of virtually unregulated antibiotic use, a voluntary approach 
seems somewhat fanciful, if not naïve. 
Second, the guidance contains an expansive reading of its first 
principle, limiting the use of medically important drugs to “those uses 
that are considered necessary for assuring animal health.”257  The 
FDA seeks to eliminate the use of antibiotics for “production 
purposes,” i.e., growth enhancement and feed conversion.258  It is 
willing to allow, however, uses that are “associated with the 
treatment, control, or prevention of specific diseases, including 
administration through feed or water.”259  It defines prevention as 
“including the administration of an antimicrobial drug to animals, 
none of which are exhibiting clinical signs of disease, in a situation 
 
 254.  Id. at 3.   
 255.  Id. at 5–17.  
 256.  Id. at 21–22.  
 257.  Id. at 21.   
 258.  Id.   
 259.  Id.  
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where disease is likely to occur if the drug is not administered.”260 
The problem with this approach is that the delivery of 
subtherapeutic levels of antibiotics to livestock for disease prevention 
is widespread and virtually inseparable from the use of those 
antibiotics as growth promotants.261 The same dosage serves both 
purposes, regardless of how the drug is labeled.  Studies have shown 
that in crowded confinement situations, livestock mortality is reduced 
by the delivery of low levels of antibiotics, even though the same 
result would likely be achieved from improved living conditions.262 
Thus, antibiotics can be used at subtherapeutic levels for disease 
prevention purposes as a means to adjust for the stressful production 
practices. Dr. Robert S. Lawrence, professor of Environmental 
Health Sciences, Health Policy, and International Health at the Johns 
Hopkins Bloomberg School of Public Health, explained this in his 
hard-hitting criticism of the FDA guidance: 
 
The secret to [this production system’s] success has been, in 
no small part, the continuous feeding of small doses of antibiotics 
to food animals throughout their lives. These drugs help animals 
grow faster, and they also stave off infections linked to the squalid 
conditions in which food animals are raised. The misuse of 
antibiotics by the food animal industry is not just a means to make 
a quick buck; misusing these drugs is the lynchpin of the industrial 
model. 
If antibiotics could no longer be used for disease prevention, 
the food animal production industry would be forced to reform its 
production practices to raise healthy animals in other ways. The 
preventive use of antibiotics would no longer be “necessary.”  By 
eliding this fact in its guidance documents, the FDA has built 
public health policy around the needs of the industry rather than 
require the industry to reform itself to assure both human and 
 
 260.  Id. at n. 5.  
 261.  See, e.g., Bonne M. Marshall & Stuart B. Levy, Food Animals & Antimicrobials: 
Impacts on Human Health, 24 CLIN. MICROBIOL. REV. 718, 719 (2011), available at 
http://cmr.asm.org/content/24/4/718.full (explaining that some of the antibiotics administered to 
feedlot animals for non-therapeutic uses are the same ones used to treat illness in both humans 
and animals). 
 262.   See, e.g., JAMES M. MACDONALD & SUN-LING WANG, U.S. DEP’T OF AGRIC , ECON. 
RESEARCH SERV., SUBTHERAPEUTIC ANTIBIOTICS AND U.S. BROILER PRODUCTION 3-7 
(2009) available at http://ageconsearch.umn.edu/bitstream/49198/2/AAEA%20broiler 
%20STA%20macdonald%20wang.pdf (discussing the studies of subtherapeutic use of 
antibiotics and evaluating use in the broiler industry). 
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animal health.263 
 
The FDA is relying upon a veterinarian’s oversight to limit use to 
situations where animals are at risk for a specific disease.  However, 
these drugs are currently sold over-the-counter.264  The FDA seeks to 
phase-in voluntary oversight and consultation, but there is little 
incentive for either the livestock industry or the pharmaceutical 
industry to do so.  Moreover, many veterinarians—who are less 
regulated than human doctors—have close ties with or receive 
financial benefits from the pharmaceutical industry.265  Others are 
employed by the livestock industry.266  Thus, the objective 
determination of “judicious use” may well be compromised.  Finally, 
because the “judicious use” approach only applies to antibiotics 
classified as medically important, it is not likely to reduce overall 
antibiotic use or their impact on the environment. 
C.  The Environmental Impact of Livestock Drugs 
The FDCA does not make any apparent connections between 
drugs fed to animals and the overall impact on the environment, e.g., 
through manure excreted.  Under the terms of the statutes, the 
requisite safety analysis appears only to consider the impact on 
human consumption.267  However, the FDA is also subject to another 
federal law, the National Environmental Policy Act of 1969 
(NEPA).268  NEPA requires all federal agencies, including the FDA, 
to evaluate each major agency action to determine whether it will 
have a significant impact on the environment.269 
 
 263.  Robert S. Lawrence, The FDA Did Not Do Enough to Restrict Antibiotics Use in 
Animals, THE ATLANTIC (Apr. 16, 2012; 11:51 AM), 
http://www.theatlantic.com/health/archive/2012/04/the-fda-did-not-do-enough-to-restrict-
antibiotics-use-in-animals/255878/.  
 264.    JUDICIOUS USE, supra note 100, at 22.  
 265.   Duff Wilson & Mimi Dwyer, Veterinarians Face Conflicting Allegiances to Animals, 
Farmers—and Drug Companies, REUTERS (Dec. 23, 2014) http://www.reuters.com/ 
investigates/special-report/farmaceuticals-the-drugs-fed-to-farm-animals-and-the-risks-posed-
to-humans/#article-3-competing-loyalties.   
 266.   See generally, Market Research Statistics—U.S. Veterinarians - 2013, AM. VETERINARY 
MED. ASS’N, https://www.avma.org/KB/Resources/Statistics/Pages/Market-research-statistics-
US-veterinarians.aspx#categories (last visited Mar. 31, 2015) (showing 20.9 percent of 
veterinarians were employed in industry jobs in 2013).  
 267.   See generally, 21 U.S.C. § 360(b) (2012) (establishing the requirements for the 
approval of new animal drugs).   
 268.   42 U.S.C. §§ 4321–4370  (2012).  
 269.   42 U.S.C. § 4332(C).   
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 1. An Overview of NEPA 
The National Environmental Policy Act (NEPA) is designed to 
encourage federal agencies to integrate environmental considerations 
into their decision making by directing them to evaluate the 
environmental impact of their proposed actions and, depending on 
that impact, to develop reasonable alternatives that have less adverse 
effects.270  It is essentially a procedural statute. To ensure that 
agencies incorporate environmental impact analysis, NEPA created 
the Council on Environmental Quality (CEQ), and the CEQ 
promulgated regulations to implement NEPA procedures.271  All 
federal agencies, including the FDA, are subject to these 
regulations.272  However, the FDA, like most federal agencies, 
promulgated its own NEPA regulations which generally follow the 
CEQ procedures but are tailored for the specific mission and 
activities of the FDA.273 
The requisite NEPA process provides for an evaluation of the 
environmental effects of any major federal action.274  There are 
several levels of possible analysis: a categorical exclusion 
determination; the preparation of an Environmental Assessment 
(EA); a Finding Of No Significant Impact (FONSI); and the 
preparation of an Environmental Impact Statement (EIS).275  Despite 
the concerns raised throughout out this article, the FDA regulations 
confidently state that “[t]here are no categories of agency actions that 
routinely significantly affect the quality of the human environment 
and that therefore would ordinary require the preparation of an 
EIS.”276 
Nevertheless, instructions provided to those submitting new 
animal drug applications provide that drug sponsors should submit 
either an EA or a claim for a categorical exclusion for certain 
actions.277  The approval of a new animal drug is included in FDA 
 
 270.   See id. (requiring agencies to include in recommendations or reports on legislation and 
action affecting the environment a statement covering the impact on the environment of that 
action, any adverse effect, alternatives, the relationship between short-term use of the 
environment and the consequences of long-term productivity, and irreversible commitments of 
resources involved).  
 271.   40 C.F.R. §§ 1500–1518 (2014).  
 272.   40 C.F.R. § 1500.3.   
 273.   21 C.F.R. § 25 (2014).  
 274.   40 C.F.R. § 1500.1.  
 275.  40 C.F.R. § 1501.4; 21 C.F.R. § 25.15.  
 276.  21 C.F.R. § 25.22.  
 277.  See FOOD & DRUG ADMIN, Environmental Impact Considerations, 
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regulations as an action that will generally require an EA.278  The EA 
will be prepared by the drug sponsor  (the applicant) although the 
FDA will be “responsible for the scope and content of EAs and may 
include different information . . . when warranted.”279  If the EA 
shows that the action will not significantly affect the environment, the 
FDA will issue a FONSI.280  The FONSI is a “document prepared by a 
federal agency stating briefly why an action, not otherwise excluded, 
will not significantly affect the human environment and for which, 
therefore, an EIS will not be prepared.”281 
The drug sponsor is thus placed in a position of assessing the 
environmental effects of its own request for approval.  Particularly 
given the financial stakes at issue, it should be no surprise to find that 
EAs prepared in this situation find no adverse environmental 
impact.282  If the drug sponsor were to find an adverse environmental 
impact, the sponsor would be expected to propose an alternative.283  
That alternative, whether a denial of approval or a restricted 
approval, would clearly work against the sponsor’s financial interests.  
Nonetheless, the FDA—with limited resources and little ability to 
generate its own environmental review—is dependent upon the 
research submitted by the sponsor.  By all appearances, the system is 
designed to result in EAs that routinely support a FONSI. 
If a “categorical exclusion” applies, a drug sponsor may not even 
have to prepare an EA.  The FDA’s website explains that this 
exclusion applies to a “category of actions that the agency has 
determined, based on past experience, do not individually or 
cumulatively have a significant effect on the human environment.”284  
The FDA includes a number of types of new animal drug applications 
in its listing of categorical exclusions, including any new animal drug 
application “if the action does not increase the use of the drug.”285  
For example, the “[a]pproval of a drug for use in animal feeds if such 
 
http://www.fda.gov/animalveterinary/developmentapprovalprocess/environmentalassessments/d
efault.htm#top (last updated Jul. 08, 2014) [hereinafter Environmental Impact Considerations].  
 278.  21 C.F.R. § 25.20(m).  
 279.  21 C.F.R. § 25.40(b).  
 280.  21 C.F.R. § 25.41.  
 281.  21 C.F.R. § 25.41(citing 40 CFR. § 1508.13). 
 282.  See, e.g., ELANCO, supra note 169 (finding that the approval of ractopamine “would 
not be expected to have any substantial adverse effect on human health or the environment”).  
 283.  21 C.F.R. § 25.40(a) (providing that “[i]f potentially adverse environmental impacts 
are identified . . . the EA shall discuss any reasonable alternative course of action that offers less 
environmental risk or that is environmentally preferable to the proposed action”).  
 284.  Environmental Impact Considerations, supra note 277. 
 285.  21 C.F.R  § 25.33(a).  
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drug has been approved under § 514.2 or 514.9 of this chapter for 
other uses.”286 
The FDA regulations provide that if an action would ordinarily 
be excluded, but “extraordinary circumstances indicate that a specific 
proposed action, may significantly affect the environment,” then an 
EA will be required.287  Examples include “[a]ctions for which 
available data establish that, at the expected level of exposure, there 
is the potential for serious harm to the environment” and “actions 
that adversely affect a species or the critical habitat” of an 
endangered species.288 
If the FDA anticipates that an undertaking may significantly 
impact the environment, or if a project is environmentally 
controversial, it may choose to prepare an EIS without having to first 
seek an EA.289  This will rarely be the case.290  However, if the EA is 
prepared and indicates that the environmental impact of the federal 
action may be significant, an EIS will be prepared.291  Again, in part 
because the applicant is responsible for preparing the EA, an EIS is 
rarely indicated; and the FDA is extremely reluctant to order such an 
analysis.292 
 2. Applying NEPA to FDA Actions: Historical Context 
When NEPA was first enacted, the FDA “initially took the 
position that [NEPA] required it to consider the environmental 
impact of every important action including, for example, the approval 
of a new drug or food additive.”293  As it became clear that this 
 
 286.  21 C.F.R  § 25.33(a)(7).  
 287.  21 C.F.R. §§ 25.15, 25.21.  
 288.  21 C.F.R. § 25.21.  
 289.  21 C.F.R. §§ 21.40, 21.42 (2014).  
 290.  See 21 C.F.R. § 25.22 (describing circumstances in which preparing an EIS without an 
EA is appropriate).  
 291.  Id.   
 292.  FDA’s steadfast refusal to prepare an Environmental Impact Statement with regard to 
the very controversial new drug application that seeks the approval of genetically engineered 
salmon.  See, e.g., FOOD & DRUG ADMIN., Genetically Engineered Salmon,  http://www.fda.gov/ 
AnimalVeterinary/DevelopmentApprovalProcess/GeneticEngineering/GeneticallyEngineered
Animals/ucm280853.htm (last visited Mar. 26, 2015); see also, HAROLD F. UPTON & TADLOCK 
COWAN, CONG. RESEARCH SERV., R43518, GENETICALLY ENGINEERED SALMON (Apr. 30, 
2014), available at http://www.fas.org/sgp/crs/misc/R43518.pdf (explaining the new drug 
application approval process as applied to genetically engineered salmon and discussing the 
NEPA review).  
 293.  PETER BARTON HUTT, RICHARD MERRILL & LEWIS GROSSMAN, FOOD AND DRUG 
LAW CASES AND MATERIALS 1309 (The Foundation Press, 4th ed. 2014).  Note that one of the 
authors, Peter Barton Hutt, served as Commissioner of the FDA  from 1971–1975, and another, 
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position was impracticable, the FDA published a Federal Register 
announcement declaring that the FDCA was its sole authority for the 
approval or rejection of any new drug or food additive.294  The agency 
sought to “precipitate a judicial challenge that would clarify its 
obligations under NEPA.”295 
As anticipated, the regulation was challenged and the agency’s 
obligations were clarified.  The Federal District Court for the District 
of Columbia struck down the limiting regulation and held that 
“NEPA requires FDA to consider environmental factors in its 
decision-making process and supplements its existing authority to 
permit it to act on those considerations.  It permits FDA to base a 
decision upon environmental factors, when balanced with other 
relevant considerations.”296  FDA revoked the contested regulation 
soon thereafter.297 
 Despite NEPA’s focus on systemic environmental concerns, 
scholars observe that the FDA has almost never taken an action that 
identified environmental effects outside the risks to health as an 
important consideration.298  And, when it has done so, it has often 
been unsuccessful.  When it denied a food additive petition on 
environmental grounds, it was sued and the court reversed its 
decision.299  Moreover, when it attempted to stay the effect of a 
regulation allowing the food additive selenium in animal feed because 
of a potential threat to aquatic fish and wildlife,300 Congress forced the 
agency to suspend the stay.301 
Over the years, there have been several unsuccessful attempts to 
force the FDA to file an EIS.  Most prominent among these were 
 
Richard Merrill, served from 1975-1977, providing them with exceptional credibility in analyzing 
the positions of the FDA during this time period.  Id. at x.  
 294.  40 Fed. Reg. 16,662 (Apr. 14, 1975).  This regulation provided that the determination 
of an adverse environmental impact had “no legal or regulatory effect” and that the FDA 
Commissioner was limited in his authority to apply the law set forth in the FD&CA.  
 295.  HUTT, MERRILL & GROSSMAN, supra note 293, at 1310 (referencing the notice 
published at 40 Fed. Reg. 16,662 (Apr. 14, 1975)).  That notice included the statement that “[i]t 
is the Commissioner’s opinion that, since the activities of the Food and Drug Administration 
directly affect every person in this country, any such person has standing to obtain judicial 
review of this regulation in accordance with the provisions of 5 U.S.C. § 701 et seq.”  
 296.  Envtl. Def. Fund Inc. v. Mathews, 410 F. Supp. 336, 338 (1976).  
 297.  41 Fed. Reg. 21,768 (May 28, 1976).  
 298.  HUTT, MERRILL & GROSSMAN, supra note 293, at 1311.  
 299.  See generally Marshall Minerals, Inc. v. FDA, 661 F.2d 409 (5th Cir. 1981).  
 300.  58 Fed. Reg. 47,962, 47,964  (Sept. 13, 1993). 
 301.  HUTT, MERRILL & GROSSMAN, supra note 293, at 1311 (citing 60 Fed. Reg. 53,702 
(Oct. 17, 1995) and 62 Fed. Reg. 44,892 (Aug. 25, 1997)).  
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efforts to object to the FDA’s approval of the genetically modified 
drug recombinant bovine somanatropin (rBST or rBGH) marketed as 
Posilac.302  The plaintiffs, suing as consumers of commercially 
produced milk, raised a number of challenges including the FDA’s 
failure to conduct an EIS.303  The FDA’s FONSI determination was 
based on an EA prepared by the drug applicant, Monsanto.304  The 
plaintiffs claimed that environmental harms—the socioeconomic 
impact on dairy farmers, health issues related to the milk produced, 
and health issues affecting the cows—required an EIS under NEPA.305  
The court disagreed, holding that FDA had met all of its 
requirements.306  There was no allegation or discussion of any 
environmental impact associated with the use of the drug itself. 
 3. Pending Challenges to FDA’s Compliance With NEPA: 
Ractopamine 
In November 2014, two new cases were filed against the FDA 
Commissioner, Margaret Hamburg, each seeking to change the 
FDA’s casual treatment of its obligations under NEPA.307  The cases 
challenge the FDA’s approval of ractopamine for use in pigs, turkeys, 
and cows without conducting an appropriate environmental analysis 
under NEPA.308 
One case was brought by the Humane Society, United 
Farmworkers of America, and the Animal Legal Defense Fund.309  It 
alleges food safety risks,310 worker safety risks,311 a negative impact on 
threatened or endangered species,312 and—most relevant to the 
discussion herein—adverse environmental impacts from ractopamine 
 
 302.  See Stauber v. Shalala, 895 F.Supp. 1178, 1182 (W.D. Wis. 1995) ([p]laintiffs challenge 
defendants’ approval of intervenor-defendant Monsanto Company’s new drug application for 
Posilac, a milk production-enhancing, synthetic bovine growth hormone drug.”). See discussion 
of rBST, supra, note 132–140 and the accompanying text.  
 303.  Id. at 1182.  
 304.  Id. at 1186.  
 305.  Id. at 1194.  
 306.  Id. at 1194–96.  
 307.  Complaint, Humane Soc’y, No. 3:14-cv-04933 at 30–31; Complaint, Ctr. for Food 
Safety, No. 3:14-cv-4932 at 21–22.  
 308.  Complaint, Humane Soc’y, No. 3:14-cv-04933 at 2; Complaint, Ctr. for Food Safety, No. 
3:14-cv-4932 at 1.  
 309.  Complaint, Humane Soc’y, No. 3:14-cv-04933.  
 310.  Id. at 10–13.  
 311.  Id. at 13–14.  
 312.  Id. at 17–18.  
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in livestock manure.313  It also challenges the approval of ractopamine 
in combination with other drugs, Tylosin, Monensin, and 
Melengestrol,  citing environmental risks.314  The Complaint alleges 
that the FDA has never adequately assessed these impacts under 
NEPA. 
The other case was brought by three organizations: the Center 
for Food Safety, the Center for Biological Diversity, and Sierra 
Club.315  It alleges food safety risks;316 the environmental risk of 
ractopamine contaminating groundwater, streams, rivers, and other 
surface waters;317 an adverse impact on threatened or endangered 
species;318 and environmental risks associated with the combination 
drugs.319 
Both cases cite the extensive use of ractopamine, use that far 
exceeds the estimates contained in the EAs prepared by the 
applicant; and both assert that the FDA has failed to adequately 
consider the environmental impacts of such extensive use.320  It 
remains to be seen how the court will respond to these allegations, 
but even the filings reflect a new awareness of the extent of drug use 
in livestock production and the associated risk of contaminated 
manure. 
V. CHARTING A PATH FORWARD 
The Humane Society and the Center for Food Safety litigation 
may bring the issues associated with animal drug use to light, at least 
with respect to the specific ractopamine usage in swine, cattle, and 
turkeys.  Unfortunately, the litigation will last some time and 
addresses only one drug. 
The FDA’s efforts to control the development of antibiotic 
resistance through its “Judicious Use” policy indicates both the 
agency’s interest in confronting the problem and its hesitancy to take 
strong action.  The FDA continues to approve new animal drugs 
 
 313.  Id. at 14–17.  
 314.  Id. at 18–24.  
 315.  Complaint, Ctr. for Food Safety, No. 3:14-cv-4932. 
 316.  Id. at 8–11.  
 317.  Id. at 11–12.  
 318.  Id. at 12.  
 319.  Id. at 13–16.  
 320.  See generally, Complaint, Humane Soc’y, No. 3:14-cv-04933; Complaint, Ctr. for Food 
Safety, No. 3:14-cv-4932. 
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regularly,321 with Freedom of Information Summaries available for 
each drug.322  Yet, these summaries fail to include environmental risks 
as a category of consideration, indicating that it is unlikely to change 
its longstanding reliance on FONSI determinations as its sole 
approach to NEPA.323 
Meanwhile, those at all ends of the livestock industry remain 
locked in a competitive struggle to produce meat at the cheapest price 
possible, and those in the pharmaceutical industry compete fiercely to 
develop and market drugs that will assist producers in achieving that 
goal.  Both industries are on a new drug treadmill that rewards the 
use of more powerful drugs to achieve more dramatic results.  There 
is no systemic analysis of the cumulative effects of these drugs’ use in 
livestock production, and without that analysis, we proceed at our 
peril. 
The use of drugs in the livestock industry is so pervasive, so 
engrained in the system, so embedded into our price structures, and 
so much a part of our overall food system, that it must be asked 
whether there is any way to retreat.  Still, the seriousness of the risks 
presented implores us to find solutions. The following proposals 
provide the possibility for an interrelated way forward, employing a 
range of policy tools from market-based to regulatory. 
A.  The Creation of a National Commission for the Evaluation of 
Drug Use in the Livestock Industry 
There are two overarching problems raised by the regulation of 
drug use in the livestock industry.  First, there is no one who is able to 
see the big picture—no one who approaches the issue of livestock 
production with a systemic analysis.  Drugs are approved on an 
individual basis with no follow-up mechanism to chart the extent of 
their eventual use.  There is never any consideration of cumulative 
multi-drug environmental or food safety effects.  Furthermore, there 
is no apparent thought about the systemic impact of creating a billion 
tons of contaminated manure and then applying it to cropland or 
allowing it to enter waterways.  Second is the closely related problem 
 
 321.  Approvals are posted on the FDA website.  Recent Animal Drug Approvals, FOOD & 
DRUG ADMIN.  (Mar. 24, 2015),  http://www.fda.gov/AnimalVeterinary/Products/ 
ApprovedAnimalDrugProducts/ucm363948.htm. 
 322.  See, e.g., FOOD & DRUG ADMIN., FREEDOM OF INFORMATION SUMMARY 
SUPPLEMENTAL NEW ANIMAL DRUG APPLICATION: ZILMAX PLUS RUMENSIN PLUS 
TYLAN PLUS MGA (2015), available at http://www.fda.gov/downloads/AnimalVeterinary/ 
Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/UCM433793.pdf.  
 323.  Id.  
11-Schneider_Final (Do Not Delete) 8/17/2015  5:20 PM 
Spring 2015] BEYOND THE FOOD WE EAT 275 
of secrecy.  Even the agency charged with regulating animal drugs 
does not have access to how or where they are being used. 
A bipartisan commission should be created to accurately 
evaluate the full extent of drug use in the livestock industry; the 
cumulative impact of this drug use; the public health and animal 
welfare effects; and the full range of environmental effects.  The 
commission would further explore public and private pressures placed 
on FDA regulators; efforts to influence research to produce results in 
line with industry objectives; and efforts to prevent transparency in 
agricultural practices.  The commission would be charged with 
reporting its findings to Congress, the President, and the public.  
Based on its findings, the commission would make recommendations 
to the relevant agencies involved, and to Congress if additional 
legislation were proposed.  This commission would have wide 
authorities to obtain otherwise privileged information and to consult 
widely with a full range of affected parties. 
B.  The Expanded Use of Certification Programs for Meat Produced 
Without Drugs 
There are producers and retailers who would like to decrease or 
eliminate livestock drugs in their operations, but the current market 
structure places them at a disadvantage.  If all meat is the same, cost 
of production is the only driver for economic success. Similarly, 
consumers who are concerned about drug use in livestock production 
may feel they have few options.  Systems for verifiable labeling serve 
both interests. 
Public and private certification programs should be encouraged, 
assisting the industry with a value-added approach to minimizing drug 
use.  This has already begun, with successful “raised without 
antibiotics” market initiatives and associated certifications.324  The 
USDA currently grades meat and poultry products and verifies some 
production practices,325 but enhanced efforts should be made to 
 
 324.  As a current example, the “Never-Ever Process Verified Program” certifies that 
livestock is raised without antibiotics administered in any form; that is raised without growth 
hormones or other synthetic growth promotants (including natural or synthetic, estrus 
suppressants, beta agonists, or other drugs to promote or impact growth); and, that it is raised 
without being fed any mammalian and avian byproducts.  See, U.S. DEP’T OF AGRIC., NEVER 
EVER 3 (NE3) (2009), available at http://www.ams.usda.gov/AMSv1.0/getfile? 
dDocName=STELPRDC5066028.  
 325.    E.g., U.S. DEP’T OF AGRIC., Grading, Certification, and Verification (Jan. 14, 2013), 
http://www.ams.usda.gov/AMSv1.0/ams.fetchTemplateData.do?template=TemplateA&navID=
GradingCertificationandVerification&leftNav=GradingCertificationandVerification&page=Gr
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develop a range of certification opportunities for drug-free 
production practices.  The USDA should actively promote these 
efforts and encourage producers and consumers to move toward the 
reduced use of livestock drugs.  Incentive programs to assist 
producers in the transition toward drug-free practices should be 
established. 
C.  A Commitment to Transparency Throughout the Food System 
Under the current regulatory system for drugs used in livestock 
production, most drugs are purchased over-the-counter or in 
proprietary feed mixes.  In this system the chemical composition of 
drugs and feed additives may be protected by patents and 
trademarks, and even regulating agencies may be unaware of industry 
practices.  Consumers are likely to be unaware of drug use, drug 
residues, and potential contamination issues.  The following steps 
would help to ensure a more transparent system. 
The Department of Health and Human Services (incorporating 
the FDA and the CDC) should be allowed access to accurate 
information about what drugs are being used.  This includes 
information about on-farm use, specific-species use, off-label use, and 
information about adverse impacts.  This would require re-
categorizing livestock drugs or establishing a new reporting system 
for livestock drug use. 
Information on drug use that is site-specific should be available 
to EPA, state environmental agencies, local and tribal governments, 
and to environmental researchers in order for the cumulative 
environmental and public health effects of use to be assessed.  This 
will not only alert agencies and governments to what is being used in 
their area, it will also assist in identifying the source of any 
contamination that may occur—be it from human or animal drug use. 
Public funding and assistance should be provided to states, tribes, 
and communities for testing water and soil samples for drug residues.  
This will allow these communities to build a database of information 
on drug residue contamination patterns from all uses. 
Additionally, meat labeling should either include mandatory 
reference to production practices involving significant drug use and/or 
information on drug use should be available to consumers on product 
websites.  Relevant government agencies including the FDA and the 
 
adingCertificationAndVerification&acct=AMSPW. 
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USDA should have dedicated consumer awareness programs to 
provide interested consumers with information about the food they 
eat and how it has been produced.  The agencies should combat 
efforts to limit transparency, encouraging disclosures rather than 
protecting industry secrecy. 
USDA residue testing should be increased, with results made 
available to the public.  In addition, regular residue testing by meat 
processors should be required in conjunction with the pathogen 
testing now conducted under a processor’s requisite HACCP system.  
The only exception should be for processors who obtain certifications 
that drugs were not used in production.326 
D. Requirements to Protect the Integrity of Veterinarians, Veterinary 
Schools, and Veterinary Associations 
Veterinarians are critical to FDA’s “judicious use” approach to 
the use of antibiotics.  Yet, currently, there is no public disclosure 
required for any of their financial connections with the 
pharmaceutical industry. Similarly, some veterinarians may be 
financially dependent upon a livestock integrator who seeks medical 
authority for drug use. Regulations should be put in place to protect 
the integrity of the veterinary profession.  
E.  Increased Public Funding for Research and Higher Standards for 
University Agricultural Research 
Much of the animal science research now undertaken at our 
public land grant universities is funded by private companies with a 
vested interest in the outcome of the studies.  Unfortunately, this can 
and often does influence the type of research that is done.  This 
funding system can also taint research results, as reported in the 
Chronicle of Higher Education in an article about Zilmax research: 
 
Scores of animal scientists employed by public universities 
have helped pharmaceutical companies persuade farmers and 
ranchers to use antibiotics, hormones, and drugs like Zilmax to 
make their cattle grow bigger ever faster. . . . 
It’s been a profitable venture for the drug companies, as well 
as for the professors and their universities.  Agriculture schools 
 
 326.   HACCP refers to the Hazard Analysis Critical Control Points system of testing for 
and controlling pathogen contamination in meat processing.  See generally HAACP. U.S. DEP’T 
OF AGRIC. (Mar. 24, 2015), http://www.fsis.usda.gov/wps/portal/fsis/topics/regulatory-
compliance/haccp. 
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increasingly depend on the industry for research grants . . . [a]nd 
many professors now add to their personal bank accounts by 
working for the companies as consultants and speakers.  More than 
two-thirds of animal scientists reported in a 2005 survey that they 
had received money from industry in the previous five years.327 
 
Unfortunately, schools of agriculture have “largely rejected 
critics’ concerns about industry cash.”328  It is reported that few 
agriculture school administrators are willing to set limits on faculty 
who accept corporate money, and confidentiality rules may prevent 
public disclosure.329 
Objective research is critical to good regulatory and policy 
decision making.  The connection between researchers (who study the 
impact of new technologies) and the manufacturers (who stand to 
benefit from the sale of those products) must be dismantled.  Public 
funding should be restored to prior levels, and agriculture 
departments at our universities should ensure that their policies 
demand objectivity and integrity from their professors.  Strict conflict 
of interest provisions and limitations on private compensation should 
be in place at all research institutions. 
F.  Increased Regulation 
The interpretation of the “safe and effective” test that is used to 
approve new animal drugs must be expanded to include an analysis of 
safety that incorporates environmental considerations and cumulative 
effects.  We must develop a more systemic, holistic approach to 
regulating our food system.  Mechanisms for tracking drug use on the 
farm and in all animal facilities must be in place so that the agencies 
can accurately evaluate the extent of use and the environmental 
consequences of that use.  In addition, the FDA must be adequately 
funded so that it can perform its own environmental assessments of 
the impact of new drug approvals, perhaps in partnership with the 
EPA and publicly funded research entities. 
Drugs deemed critical for human medical use should be banned 
in livestock production absent extraordinary circumstances, such as a 
 
 327.  Melody Petersen, As Beef Cattle Become Behemoths, Who Are Animal Scientists 
Serving?, CHRON. OF HIGHER EDUC. (Apr. 15, 2012), http://chronicle.com/article/As-Beef-
Cattle-Become/131480/ (criticizing the influence of industry funding on animal science 
research).  
 328.   Id.  
 329.   Id.  
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major livestock epidemic.  Drug uses that increase animal suffering in 
any way should similarly be prohibited.  Relatedly, new drug 
approvals should be guided by a safety analysis that truly includes 
consideration of the safety of the animal to which the drug is 
administered. 
Companies and persons found to have used a drug inconsistently 
with label directions and approved usage should bear financial 
responsibility for remediating drug contamination of soil and water.  
Finally, the associated adverse effects on the environment should be 
assessed on companies marketing the drug for farm use and on 
anyone found to have not used the drug consistent with label 
directions and approved dosage. 
G.  Campaign Finance Reform and Restrictions on Industry Lobbying 
The lack of regulation of drugs in the livestock industry is all too 
often traced back to Congressional pressure on an under-resourced 
agency.  Intimately intertwined with campaign funding, this 
Congressional pressure all too often influences policies that should be 
decided on the merits.  As noted herein, efforts to prevent limitations 
on antibiotic use in livestock production have been obvious and 
largely successful, despite increasing public health concerns 
worldwide.  As long as our political system is influenced most by 
those with the most funds to invest in it, it will be extremely difficult 
to enact thoughtful, objective public policy. 
VI. CONCLUSION: A NEW VIEW OF OUR FOOD SYSTEM 
The industrialization of our food production systems—namely 
the use of a manufacturing model for the production of food—has led 
many to forget that food is not just another manufactured item.  Our 
food begins as a living thing, whether plant or animal, and it grows 
through natural biological processes.  One process affects another, 
and each interacts with the environment. 
Yet, our regulatory systems treat each aspect as if it were in 
isolation.  Our system for regulating drug use seems to discount the 
fact that what an animal ingests will be present in that animal’s 
system, in the products of that animal, and in the manure and urine it 
excretes.  It ignores the fact that all of the drugs used may have a 
cumulative, even a synergistic effect, that far exceeds the analysis of 
any individual drug.  Our food system is just what it claims to be—a 
system—and it is a system that is deeply intertwined with and 
dependent upon the environment.  We need to stop regulating 
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individual components without regard for the whole. 
In the end, consumers have a critical role to play.  Michael 
Pollan’s oft-quoted comment about “eating as a political act,” an 
extension of Wendell Berry’s saying that “eating is an agricultural 
act,” remains the most realistic avenue for a change.330   
Ultimately, it may be consumers’ increasing interest in their 
food—where it comes from and how it was produced—that has the 
most impact on our future.  Industry responds to the marketplace.  
Whether it is Chiplotle marketing its “food with integrity;”331 Tyson 
Foods essentially halting the use of Zilmax throughout the industry;332 
or efforts in the poultry industry to eliminate the use of antibiotics;333 
companies react to consumer interests.  Assuring that consumers have 
the information they want and need will go a long way towards 
improving the food system upon which we all depend. 
 
 330.   See Joe Fassler, The Wendell Berry Sentence That Inspired Michael Pollan's Food 
Obsession, THE ATLANTIC (Apr. 13, 2013), http://www.theatlantic.com/entertainment/ 
archive/2013/04/the-wendell-berry-sentence-that-inspired-michael-pollans-food-
obsession/275209/ (discussing how connecting the dots between the farm and the plate leads to 
more change in the industry).  
 331.  What is Food with Integrity?, CHIPOTLE, http://www.chipotle.com/en-US/fwi/fwi.aspx 
(last visited Mar. 28, 2015).  
 332.  Lost Hooves, supra note 160.  
 333.  David Kesmodel et al., Meat Companies Go Antibiotics-Free as More Consumers 
Demand It, WALL ST. J. (Nov. 3, 2014), http://www.wsj.com/articles/meat-companies-go-
antibiotics-free-as-more-consumers-demand-it-1415071802. 
